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Abstract 
 
The skeletal system forms the mechanical structure of the body and consists of 
bone, which is hard connective tissue. The tasks the skeleton and bones take 
over are of mechanical, metabolic and synthetic nature. Lastly, bones enable the 
production of blood cells by housing the bone marrow. Bone has a scarless self-
healing capacity to a certain degree. Injuries exceeding this capacity caused by 
trauma, surgical removal of infected or tumoral bone or as a result from treatment-
related osteonecrosis, will not heal. Critical size bone defects that will not heal by 
themselves are still object of comprehensive clinical investigation. The 
conventional treatments often result in therapies including burdening methods as 
for example the harvesting of autologous bone material. The aim of this thesis 
was the creation of a prevascularized bone implant employing minimally invasive 
methods in order to minimize inconvenience for patients and surgical site 
morbidity. The basis for the implant was a decellularized, naturally derived 
vascular scaffold (BioVaSc-TERM®) providing functional vessel structures after 
reseeding with autologous endothelial cells. The bone compartment was built by 
the combination of the aforementioned scaffold with synthetic β-tricalcium 
phosphate. In vitro culture for tissue maturation was performed using bioreactor 
technology before the testing of the regenerative potential of the implant in large 
animal experiments in sheep. A tibia defect was treated without the anastomosis 
of the implant’s innate vasculature to the host’s circulatory system and in a 
second study, with anastomosis of the vessel system in a mandibular defect. 
While the non-anastomosed implant revealed a mostly osteoconductive effect, 
the implants that were anastomosed achieved formation of bony islands evenly 
distributed over the defect. 
In order to prepare preconditions for a rapid approval of an implant making use 
of this vascularization strategy, the manufacturing of the BioVaSc-TERM® as 
vascularizing scaffold was adjusted to GMP requirements.
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Zusammenfassung 
 
Das Skelett bildet die mechanische Struktur des Körpers und besteht aus 
Knochen, einem harten Bindegewebe. Knochen übernehmen mechanische, 
metabolische und synthetische Aufgaben. Schlussendlich ermöglichen Knochen 
die Synthese von Blutzellen durch die Beherbergung des Knochenmarks. Wird 
die Heilungskapazität von Knochen durch Trauma, operative Entfernung von 
infiziertem oder tumorösem Knochen oder als Ergebnis behandlungsbedingter 
Osteonekrose, überschritten, findet keine vollständige Heilung statt. 
Knochendefekte, die eine kritische Größe überschreiten, sind daher immer noch 
Gegenstand umfangreicher, klinischer Forschung. Bei herkömmlichen 
Behandlungsmethoden können Eingriffe notwendig werden, die den Patienten 
belasten, wie bei der Gewinnung von autologem Knochenmaterial. Das Ziel der 
vorliegenden Arbeit war die Herstellung eines prävaskularisierten Implantats 
unter Verwendung minimalinvasiver Methoden, um die Belastung von Patienten 
und die Morbidität an der Entnahmestelle, zu verringern. Zur Herstellung eines 
vaskularisierten Implantats bildete ein dezellularisiertes Darmsegment (Jejunum) 
porcinen Ursprungs die Grundlage (BioVasc-TERM®). Diese Trägerstruktur 
stellte ein funktionales Blutgefäßsystem nach Wiederbesiedelung mit autologen 
Endothelzellen bereit. Der Knochenanteil des Implantats wurde durch die 
Kombination der genannten Trägerstruktur mit dem synthetischen 
Knochenersatzmaterial β-Tricalciumphosphat gebildet. In-vitro-Kultivierung in 
einem Bioreaktor führte zur Reifung des Implantats vor der Testung seines 
Potenzials zur Knochenregeneration in Großtierversuchen bei Schafen. Ein 
Tibiadefekt wurde behandelt ohne die Anastomose des implantateigenen 
Gefäßsystems an den Blutkreislauf und ein Mandibeldefekt wurde mit 
Gefäßanschluss behandelt. Das Implantat ohne Gefäßanschluss hatte einen 
osteokonduktiven Effekt, während das anastomosierte Implantat zur Bildung 
zahlreicher Knocheninseln, gleichmäßig über den Defekt verteilt, führte. Um eine 
zügige Zulassung eines Implantats, das diese Strategie zur Vaskularisierung von 
Knochen nutzt, zu ermöglichen, wurde die Herstellung der BioVaSc-TERM® an 
die Vorgaben der Guten Herstellungspraxis angepasst.
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 Introduction 
1.1 Bone 
1.1.1 Bone structure 
The functions of bone include structural support of the body, the protection of 
internal organs, facilitation of movements, cell production and mineral storage. 
Bone is a very dynamic tissue in a constant process of growth, modeling and 
remodeling. Growth of bone can take place in two different processes. In the so-
called endochondral ossification, bone is created over the intermediate step of 
cartilage formation. This type of bone growth contributes to longitudinal growth of 
long bones at the growth plates in the epiphyseal plate. During longitudinal 
growth, chondrocytes proliferate constantly and lay down cartilage that pushes 
the diaphysis outwards. Osteoblasts mineralize the cartilage in order to form new 
bone. The second variant of bone formation is the intramembranous ossification 
during which no transitional cartilage is formed. Mesenchymal progenitor cells 
from the embryonal connective tissue condense to form dense clusters. Those 
cells develop into osteoblasts laying down bone matrix and eventually becoming 
osteocytes. Bone modeling is the adaption in shape depending on mechanical 
forces. Bone can progressively adjust to the physical signals it is exposed to. 
During this process, bone formation and resorption are not as closely linked as it 
is the case in remodeling [1]. Remodeling is the mechanism of bone resorption 
and formation as a response to physiological requirements and as a steady 
process in order to eliminate micro damage. Mechanical stimulation results in 
improved bone structure especially if mechanical load is applied at discrete 
intervals instead of one long uninterrupted period, because cells need several 
hours for resensitization [2]. 
The three major components of bone are minerals, collagen type I and water. 
Depending on the type of bone, the relative proportions vary, especially 
proportions between mineral and water, while the relative amount of collagen 
remains the same [3].  
Introduction 
2 
 
The collagenous protein amount makes up about 90 % of the organic matrix with 
the remaining 10 % consisting of osteocalcin, osteonectin, osteopontin, 
fibronectin, bone sialoprotein and bone morphogenic proteins (BMPs) [4, 5]. 
The inorganic phase of bone consists of phosphate and calcium as well as 
bicarbonate, sodium, potassium citrate, magnesium, carbonate, fluorite, zinc, 
barium, and strontium [5]. 
The characteristic cell types of bone include osteoblasts, osteoclasts, osteocytes, 
osteoprogenitors and lining cells. Osteoblasts derive from mesenchymal 
progenitor cells; they are the bone forming cells, act as groups, and secrete the 
bone matrix. They are thus the main source for collagen in bone tissue and 
subsequently mineralizing the bone matrix. The collagenous ground substance 
before mineralization is the so-called osteoid. As mineralization follows, the 
osteoid transforms into an osteon, the primary functional unit of cortical bone [6]. 
The osteoid and inactive bone tissue in general are covered with quiescent 
osteoblasts in a flattened morphology [7]. In this mode, they are called the bone 
lining cells and act as a blood-bone barrier by controlling the influx and efflux into 
and out of the bone extracellular fluid. They can differentiate into osteoblasts 
again by parathyroid hormone or mechanical force [8]. Osteoblasts surrounded 
by mineralized matrix become osteocytes, a scattered cell type embedded in an 
extensive network of canaliculi that connects them to other osteocytes, the bone 
lining cells on the surface and osteoblasts. They make up the majority of bone 
cells and are responsible for important functions within the bone [9, 10]. The 
canaliculi network allows for cell-cell communication between osteocytes and 
provide a mechanosensory capacity which is a prerequisite for the adaption to 
mechanical forces [11, 12]. It was suggested that, appropriate to the stimuli they 
register, osteocytes regulate the activity of osteoblasts and osteoclasts. This way, 
they are a main control unit of remodeling [13, 14]. Mechanical stress for example 
results in the production of different growth factors by osteocytes which lead to 
bone production [5, 15]. On the contrary, physical unloading elicits the expression 
of various proteins reducing bone formation by inhibiting the Wnt signaling 
pathway [16]. Apoptosis of osteocytes functions as chemotactic signal for 
osteoclast attraction [17]. MSCs, osteocytes and osteoblasts contribute to 
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osteoclast formation which enables bone resorption [18]. Osteoclasts acidify their 
surrounding and dissolve bone minerals while the protease cathepsin K 
catabolizes collagens, elastin and gelatin and thus effectively breaks down the 
proteinaceous aspect of bone [19]. The range of influence of the acidic 
environment is confined by the so-called sealing zone. It seals the resorbing 
compartment, namely the extracellular space in which bone resorption takes 
place [20]. 
All these components make up the bone as a discrete system that allows de novo 
bone formation, growth, remodeling and adaption to requirements arising from 
the outside environment as well as healing and its functions as structural 
supportive organ. 
 
1.1.2 Bone healing and blood supply 
In case of injury, two modes of healing exist, primary and secondary bone 
healing. Primary bone healing can only take place in areas of functional 
periosteum and when the fracture ends are in direct contact to each other [21]. 
Depending on the size of the gap, osteoblasts of the endosteum are activated 
and new bone is generated in the gap until the osteons of both fracture ends fuse. 
This mode of healing occurs in gaps smaller than 0.01 mm and is a rare natural 
process of fracture healing [22]. The second mode of primary bone healing occurs 
in gaps up to 1 mm [23]. In this case, the gap is bridged with perpendicularly 
oriented lamellar bone, which is then, in a second step, reorganized by cutting 
cones corresponding to the process described before. Only after the 
reorganization, the bone regains its biomechanical properties [22, 24]. 
Secondary bone healing is more frequent and consists of endochondral and 
membranous bone formation. In contrast to primary bone healing, gentle 
movement and weight bearing support it. Blood entering the fracture gap builds 
a hematoma and an inflammatory response is initiated. Granulation tissue and 
connective tissue formation connect fracture ends flexibly and limit movements 
during the endochondral ossification. At the same time, intramembranous 
ossification occurs beneath the periosteum close to the fracture ends and results 
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in a hard bony callus surrounding the soft fibrocartilaginous callus, gradually 
mineralized by activated osteoblasts [25]. 
In bone, as in other tissues, the formation of new vascular networks is vital for 
the regenerative potential. The entry of blood vessels into the avascular cartilage 
during endochondral ossification is essential for further bone formation. The 
blood flow within bone is closely connected to its metabolic activity and is a 
common limiting factor in regeneration [26]. The creation of blood vessels in 
embryogenesis is achieved by vasculogenesis, the de novo formation of blood 
vessels. During this process, mesodermal cells differentiate into hemangioblasts 
and migrate to sites of simple blood vessel formation [27]. The second mode of 
blood vessel formation is angiogenesis, a mechanism responsible for the vast 
majority of vascular networks. The term describes the extension of existing 
vasculature by branching and sprouting. This mechanism is characterized by 
endothelial cells, which grow toward an angiogenic stimulus such as VEGF, 
PDGF or FGF [28, 29]. Although angiogenesis is following the same principles in 
all tissues, it is discussed that blood vessels become specialized depending on 
the hosting tissue [27, 30]. The hierarchal topography and organization of the 
vasculature in bone is similar to other organs: an artery provides a delicate vessel 
network with blood flow, which is directed away by a vein. 
The necessity of endochondral angiogenesis for endochondral ossification 
reflects the close connection of bone regeneration to blood supply. Blood vessels 
invade hypertrophic cartilage and only then, a progression of bone formation is 
taking place [31]. The release of growth factors by maturing chondrocytes 
ensures further expansion of the vasculature in the growth plate [32]. 
Comprehensively, different sources provide for the profuse blood supply and thus 
healing capacity of bone. In long bones, the nutrient artery enters the medullary 
cavity and supplies the bone marrow and feeds into the endosteum [33]. 
Additionally, the artery anastomoses with metaphyseal and epiphyseal vessels. 
The metaphyseal capillary network derives from system blood vessels that 
directly drive into the metaphysis and support the blood flow provided by the 
nutrient artery [34]. The epiphyseal arteries enter the epiphysis through discrete 
openings in the bone. They supply the ossification centers and while the growth 
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plate itself is avascular, it receives nutrients from the metaphyseal and epiphyseal 
vessels [35]. 
The blood supply of the outer surface of bone is achieved by the periosteum, a 
tissue consisting two layers, the outer fibrous and the inner cambium layer. The 
vascular structures of the periosteum cover the entire length of bone shafts. They 
supply the outer third of compact bone by entering the Volkmann’s channels and 
the Haversian system [36]. In bone regeneration, the periosteum is – apart from 
its role in blood supply – of exceptional importance as source of osteoprogenitor 
cells and growth factors [37]. The periosteum’s influence on bone healing was 
demonstrated in numerous studies. 
 
1.1.3 Bone defects 
Despite bone’s high regenerative capacity of scarless healing, there are 
numerous scenarios that necessitate clinical support for bone healing. Trauma, 
healing disorders, malignant tumor removal as well as infection, osteomyelitis or 
radiation/medication-related osteonecrosis are causes for impaired healing or so-
called critical size defects. The accurate definition of a critical size defect 
describes the smallest possible defect that does not heal during the lifetime of an 
organism [38]. Traumatic bone defects are usually result of high force impacts or 
stress caused by falls, road traffic or ski accidents [39]. In this case, the bone 
itself is healthy and is damaged by external factors. A pathological fracture in 
contrast is a bony defect resulting from diseases that weaken the structure of the 
bone with a resulting injury from common loads during everyday life. 
 
1.2 Tissue engineering and bioreactor technology 
Today’s view on tissue engineering (TE) affiliates this field of study with the 
development of biological substitutes that have the ability the replace 
degenerated or diseased tissues or defective organs in order to restore their 
designated function as for example in bone, when critical size defects do not heal 
naturally [40]. Classically, cellular components, undergoing application-specific 
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treatment e.g. genetic modification or physical and chemical stimulation in vitro, 
are combined with supportive biomaterials. This illustrates the interdisciplinary 
nature of tissue engineering, which integrates cell biological science, medicinal 
findings and material science, as well as bioreactor engineering. The 
understanding of cellular behavior towards materials and surfaces, cells are in 
contact with, gives guidance to material scientists to develop materials or surface 
modifications that either provide an environment for cell-specific niches or help 
directing cell fate into a desired linage [41]. In the narrow sense, tissue 
engineering starts exactly at the point when conventional 2D culture conditions 
turn to 3D conditions during tissue generation; this is when suitable cells, usually 
stem cells or differentiated primary cell types, get seeded on a 3D matrix that 
already fosters basic tissue development processes [42]. With progressing tissue 
generation, increasing volumes necessitate techniques that allow for optimal 
supply of nutrients and oxygen. Thus, the development of bioreactors closely 
interconnects with the progress in tissue engineering. Bioreactors provide the 
possibility of influencing cells by the exertion of physical regulatory signals 
encouraging cells to maintain their phenotype or to differentiate [43]. In 
vascularized bone tissue engineering, perfusion of scaffolds can help 
upregulating osteogenic markers, while shear stress in vascular structures 
caused by continuous medium flow contributes to vascular patency and 
endothelial cell health [44]. The general aim is creating conditions in vitro that are 
as close as possible to the in vivo condition. This objective naturally leads to the 
opportunity to derive findings from in vitro models and compare them to the in 
vivo situation. For example, well-characterized cell types in specific environments 
allow the prediction of the effects of pharmaceuticals and investigation of natural 
biological processes or pathologic conditions without the necessity of in vivo 
experimentation [45].  
Another aspect is the transportation of completed complex tissue engineered 
implants from the site of manufacture to the clinical site. For the preservation of 
the integrity of vital grafts, it is necessary to provide optimal conditions in a mobile 
bioreactor system. The control of temperature and gas composition (among 
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others like pressure regime, perfusion) can be relevant parameters depending on 
the tissue to be transported.  
 
1.3 Relevant cell types for bone tissue engineering 
The following chapter will address the cell types relevant for the tissue 
engineering of a prevascularized bone graft as realized in this thesis. The cell 
types were chosen for their unique properties while other approaches might 
successfully use other cell types. 
 
1.3.1 Mesenchymal stem cells 
Mesenchymal progenitor cells (MSCs) were first discovered 1976 in bone marrow 
and described as fibroblasts with the ability to commit to the osteogenic linage. 
Today, further sources for mesenchymal stem cells are muscles, fat, blood, 
periosteum, dental pulps, lung and bones [46]. Bone marrow and fat derived 
mesenchymal stem cells are frequently used for scientific purposes due to their 
accessibility [47]. They possess high potential for proliferation, self-renewal and 
the ability to differentiate into various cell types. Adipocytes, chondrocytes and 
osteoblasts are possible target differentiations as well as myoblasts, stromal cells 
and fibroblasts [48]. The antigen profile of mesenchymal progenitor cells has 
been under extensive investigation in order to characterize them on a molecular 
biological level. The results showed a general expression of the following 
markers: CD9, CD10, CD13, CD29, CD34, CD44, CD49d, CD49e, CD54, CD55, 
CD59, CD105, CD146, CD166. While they are negative for the markers: CD3, 
CD4, CD11c, CD14, CD15, CD16, CD19, CD31, CD34, CD38, CD45, CD56, 
CD61, CD62P, CD104, CD144 [49]. It was revealed that the expression profiles 
differ dependent on the origin of the cells. For example, progenitor cells from fat 
are positive for CD49d and negative for STRO-1 and CD106 while bone marrow-
derived MSC show the opposite expression of those markers. MSC are a 
heterogeneous population of cells that display different amounts of differentiation 
potential and plasticity. Due to the complex expression profiles of antigens for the 
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verification of MSC the International Society for Cellular Therapy (ISCT) proposed 
the following characterization: 95 % of cells have to express the factors CD73, 
CD90 and CD105, while 98 % of cells have to be negative for CD14, CD35, CD45, 
CD79α and HLA-DR. According to the definition, the cells additionally have the 
ability to adhere to plastic surfaces under standard culture conditions and can 
differentiate into adipocytes, chondrocytes and osteoblasts [50]. 
MSC exhibit a number of attributes that make them attractive for the application 
in tissue engineering. They can secrete bioactive molecules that inhibit apoptosis 
of surrounding cells, reduce scar formation and fibrosis in damaged tissue, induce 
angiogenesis and thus establish blood supply [51]. They are also capable of 
stimulating proliferation of tissue-specific progenitor cells [52]. 
 
1.3.2 Microvascular endothelial cells 
The inside of blood vessels is lined with endothelial cells (ECs) which regulate 
the exchange between bloodstream and the surrounding tissue. They possess 
and keep the ability to proliferate for their lifetime and to adjust their number and 
alignment according to the requirements of the surrounding [53]. Virtually all 
tissues are dependent on blood supply guided by vessels made up by endothelial 
cells. They are capable of extending vascular networks and thus facilitate growth 
or healing of tissues [54]. 
Arteries and veins possess a wall of connective tissue und smooth muscles 
whose diameter is dependent on the vessel size. Small diameter vessels like 
capillaries and sinusoids lack the muscle and connective tissue layer and 
possess only an incomplete endothelium in order to allow for the exchange of big 
molecules between bloodstream and tissue as for example in the liver. [55]. 
Endothelial cells conserve their ability for cell division and migration as 
requirement for the formation of vessels by angiogenesis. New vessels develop 
by sprouting from existing vessels. Vessel formation sets in as answer to specific 
signals that induce endothelial cells to form extensions that guide the developing 
sprouting while growing into surrounding tissue. First, cells form a dense sprout 
that converts into a tube like structure by the fusion of the cells’ vacuoles. The 
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result is the canal of a capillary. Angiogenesis is strongly dependent on the 
surrounding extracellular matrix of adjacent cells. Endothelial cells for example 
produce laminin that facilitates the establishment of capillaries [56]. 
Cells suffering from hypoxia release angiogenesis promoting growth factors in 
order to induce an extension of the blood vessel system. A four-stage process is 
initiated by such growth factors. Proteases breach the basal lamina, cells migrate 
towards the source of the signal while proliferating and eventually forming a 
channel for the intake of the bloodstream. These steps can be triggered 
individually or simultaneously for example by the growth factor vascular 
endothelial growth factor (VEGF) that specifically affects endothelial cells [55]. 
The complexity of the vascular endothelium lies in the number of biological 
functions it fulfills. It guides the blood circulation without provoking platelet 
aggregation or leucocyte adhesion while inhibiting smooth muscle cell 
proliferation [57, 58]. Vasoconstrictive and vasodilatory mechanisms, i.e. 
recognition of hormones, physiological chemical signals, orchestrate the vascular 
tone and provide suitable blood fluidity in all conditions, so that the blood 
circulation can fulfill its function as interface between blood, organs and tissues. 
The endothelium selectively distributes macromolecules to their place of 
consumption, releases waste products into the bloodstream and regulates the 
recruitment of blood circulating cells into extravascular tissues [59]. This plays a 
crucial role for example in angiogenesis, vasculogenesis and during wound 
healing, as control of inflammation is another of its function. Environmental cues, 
mechanical forces and inflammatory and angiogenic stimuli regulate the 
endothelium [59]. 
 
1.3.3 Endothelial progenitor cells 
In general, the term endothelial progenitor cells (EPCs) describes cells capable 
of decisively influencing angiogenesis and vasculogenesis. Angiogenesis is the 
process of vessel formation by sprouting from an existing vessel while 
vasculogenesis addresses the formation of vessels without former precursor (de 
novo) [60]. 
Introduction 
10 
 
There are numerous methods to isolate EPCs and many different marker profiles 
defining different subpopulations of EPCs that have different functions and 
contributions to vessel formation. The term ‘true EPC’ is discussed controversially 
[61]. Hematopoietic cells are known to participate in angiogenesis and are found 
at the site of injured vessels, but studies also suggest, that they do not directly 
form functional endothelium but secrete factors aiding the angiogenic actions of 
resident endothelial cells  [62, 63]. The nonhematopoietic EPCs in contrast are 
more apt to actual de novo vessel formation [64]. 
Therefore, the two major classifications of EPCs are hematopoietic and 
nonhematopoietic EPCs. They differ in origin as well as methods of isolation. 
Their contributions to angiogenesis or vasculogenesis base on different modes 
of action [64]. 
Asahara et al. first isolated endothelial progenitor cells (EPCs) in 1997. The 
discovery concerns a hematopoietic cell population in adult blood capable of 
inducing de novo vessel formation. There is no unique marker identifying this type 
of cell. Animal models showed the capability of ischemic rescue and peripheral 
limb ischemia in such CD34+ hematopoietic EPCs [65]. In human trials, CD133+ 
cells showed potential for treatment of myocardial and peripheral ischemia [66]. 
Thus, circulating hematopoietic EPC can be targeted by CD34 and/or CD133 
positive cell characterization. Due to their role in enhancing angiogenesis rather 
than directly forming vessels, they are also referred to as circulating angiogenic 
cells. Since the regenerative and proliferative capacity in mature endothelial cells 
is limited, there was consensus about the existence of a circulating cell type [67]. 
Nonetheless, it has been shown that in response to injury a endothelial cell 
population is capable of extensive proliferation [68]. This cell population is 
residual in the tunica intima - the innermost layer in a blood vessel - and it was 
recently identified as CD117 expressing EPC [69]. The nomenclature for 
nonhematopoietic EPCs derives from their characteristic to grow out from 
endothelium and are thus called “outgrowth endothelial cells / endothelial 
outgrowth cells” (OECs or EOCs). An additional term is “endothelial colony 
forming cells“ (ECFCs) describing their tendency to form colonies after isolation 
from mononuclear blood derived cells [70]. They usually do not express CD41 
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[71]. Still, this classification is not complete. Bou Khazam et al. describe different 
morphologies and functions for EOCs (in this case: early outgrowth cells)  and 
ECFCs [72]. The proliferation of EOCs is very limited as is their ability to form 
tube-like structures; they probably do not actively integrate into vasculature and 
act via paracrine factors, which makes them more similar to hematopoietic EPCs. 
ECFCs in contrast have been shown to become part of newly formed blood 
vessels [73]. The application of EPC in the context of bone regeneration led to 
interesting results. In a sheep model, a 3.2 cm defect in the tibia was created and 
treated with EPC transplantation with good results regarding bone volume 
regeneration [74]. A similar approach was applied in clinical practice in a case 
report [75]. A patient with tibial fracture received an open reduction and internal 
fixation. The treatment resulted in a nonunion and was hereinafter successfully 
treated with granulocyte colony stimulating factor (G-CSF) mobilized CD34+. G-
CSF lead to detachment of some of the cells of the hematopoietic linage from 
their bone marrow surrounding. The cells entered the peripheral bloodstream and 
were collected by apheresis. A subsequent FACS sorting resulted in the isolation 
CD34+ hematopoietic EPCs. An absorbable collagen scaffold was used to 
immobilize the cells at the site of the defect additionally to bone grafting using 
autologous cancellous bone from iliac crest. 
 
1.3.4 Synergies in MSC and EPC 
MSCs and EPCs each for themselves exhibit attributes that make them suitable 
for the use in bone tissue engineering. The combined use of the cell types can 
result in synergies due to the employment of different pathways towards bone 
formation that further improve the possibilities in their application [76]. 
A calvarium defect in rats filled with ß-TCP as control and ß-TCP seeded with a 
coculture of MSCs and EPCs as testing sample showed and increased amount 
of bone found in the testing samples were double the bone area was formed as 
compared to controls after 12 weeks [77]. In a similar fashion, significantly 
increased bone density was detected in a rabbit segmental bone defect. 
However, bone area and height were similar in this case [78]. Apart from 
promoting bone formation by providing enhanced conditions for angiogenesis 
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and the prevention of the central necrosis in regeneration bone, it is discussed 
that EPC also participate in actual bone formation by differentiating into 
osteogenic cells themselves [74, 79]. The findings are supported by other in vitro 
and in vivo experiments investigating the bone regenerative potential of CD34 
positive EPCs  [80, 81]. Yet, these discoveries are not undisputed: a series of 
other studies could not illustrate an increased bone formation associated with the 
activity of EPCs alone [82, 83]. The difficulty of identification of subpopulations of 
EPCs is suspected to be the reason for the contradicting results as they might 
act differently from each other.  
 
1.4 Strategies for bone regeneration 
In Europe, the number of patients undergoing bone reconstruction surgeries is 
greater than one million per year [84]. The complexity and variety of different 
bone defect settings gave rise to a multitude of approaches aiming at the 
restoration of lost or injured bone. The following chapters give an overview on 
strategies for bone regeneration that are similar or otherwise connected to the 
methods in this thesis. 
 
1.4.1 Synthetic biomaterials 
As no biomaterial to date can replace bone regarding its mechanical properties, 
the biodegradability is an important aspect for implanted material. Bone defects 
are stabilized by metal plates and filled with bone substitute material, so that their 
mechanical properties are secondary. Therefore it is important to control the 
degradation rate of a biomaterial in order to allow for rapid replacement of the 
material by natural bone [85]. General requirements to bone substitute materials 
include interconnected porous structures with 90 % porosity. The pore diameter 
should range from 100 – 500 µm in order to allow for cell seeding and the ingrowth 
of bone tissue, including blood vessels and the exchange of nutrients and waste 
products [86]. Porosity in the range of 2 – 10 µm is crucial for the initial adhesion 
of proteins and cells, as well as migration [87]. 
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Biodegradable ceramics were the first synthetic biomaterials used in bone 
regeneration [88]. Ceramics in the form of calcium sulfate have osteoconductive 
attributes; the osteoinductivity of calcium sulfate was suggested by the reduced 
pH during calcium sulfate dissolution. The local pH reduction results in local bone 
demineralization leading to a release of osteoinductive proteins [89, 90]. It has 
been used in numerous studies proving its biocompatibility and rapid 
biodegradability [85]. Following calcium sulfates, calcium phosphates gained 
scientific interest, due to their similarity to the inorganic phase of natural bone. 
Calcium phosphates are considered biocompatible and osteoconductive with 
osteoinductive potential [91]. Their chemical and morphological attributes are well 
controllable via manufacturing conditions. It is possible to adjust surface area and 
porosity, which have an influence on the biological responses in bone 
regeneration [88, 92]. The most common forms of calcium phosphate used in 
bone regeneration are hydroxyapatite and β-tricalcium phosphate (β-TCP). Both 
materials share similar biological characteristics but differ significantly in 
degradation rate. Hydroxyapatites have a very slow degradation rate that can 
lead to remnants of the material in a defect site for years, making the area 
vulnerable to fatigue fractures [88, 93]. In β-TCP, the degradation rate is much 
higher, making it possible to control degradation rate by combining 
hydroxyapatite with β-TCP in a biphasic ceramic. 
Similar to the aforementioned materials, bioactive glass is both osteoconductive 
and osteoinductive [94]. Bioactive glass was the first artificial material able to 
chemically bond to bone [87]. Contact of the material to physiological fluids 
results in the local formation of hydroxyapatite to which bone can bond and bone 
growth is promoted by the release of physiological concentrations silica and 
calcium ions [95, 96]. 
Different materials share certain properties and differ in other aspects. In the case 
of hydroxyapatite and calcium phosphate, it can be beneficial to combine different 
materials in composites. There is a magnitude of material combinations available, 
examples are polymers, chitosan composites, bioactive glass and ceramic 
combinations. 
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1.4.2 Bone graft prefabrication following the in vivo bioreactor 
principle 
A tissue engineering strategy for bone regeneration similar to the approach in this 
thesis is the technique of the in vivo bioreactor principle. Instead of in vitro 
maturation and vascularization this method uses the patients’ own bodies as 
place of bone graft generation. Thus, the term “in vivo bone graft bioreactor 
principle” emerged [97]. 
The muscular flap is an obvious option for the in vivo bioreactor principle due to 
muscles’ high degree of vascularization and good accessibility. Additionally, 
muscles are a source of progenitor cells for bone healing [98]. It was suggested 
that muscle satellite cells contribute to bone regeneration in case of damaged or 
absent periosteum [99]. Satellite cells provide a source of growth factors as 
BMPs, IGF-1 and FGF-2 [100]. First in 1991, a muscle flap was inserted into mold 
of a rat femur cast using inert silicone. BMP-3 was injected into the flap and after 
10 days in vivo, the muscle inside the mold transformed into newly formed, mainly 
cancellous bone [101]. In another study, a collagen I carrier mixed with BMP-2 
was wrapped around the tip of a latissimus dorsi muscle flap in rats. After 3 
weeks, the flap – depending on the used dosage of BMP-2 (2 – 50 µg) – resulted 
in ectopic trabecular bone formation. Whereas in the control without BMP, there 
was no bone formation detectable [102]. This indicates muscle flaps provide a 
suitable environment for vascularization and bone formation if strong osteogenic 
promoters (e.g. BMPs) are supplementally present. 
A variation of the muscular is the periosteal flap technique. In fact, its availability 
is limited but the periosteum can be a major factor regarding bone regeneration. 
Thus, it can be used successfully whenever periosteum is available. The fibrous 
outer layer is responsible for the stability of the periosteum. Blood vessels that 
supply the bone itself and adjacent skeletal muscle traverse it. The inner 
cambium contains mainly mesenchymal progenitor cells, differentiated 
osteogenic cells as well as osteoblasts and fibroblasts [103, 104]. Within its niche 
in the bone environment, it participates in the membranous and endochondral 
ossification. Thus, it is reasonable to use its potential to investigate the suitability 
of the periosteal flap as a bone forming aspect. Typically, the flap is used to cover 
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a tissue engineered construct that contains progenitor cells and/or osteogenic 
signals in order to trigger a bone healing reaction exploiting the favorable 
preconditions of the periosteum [97]. Apart from the periosteum’s ability to 
secrete growth factors as BMPs, TGF-ß1 and IGF-1 [97, 105], the provision of a 
dense vascular network is an major advantage of the tissue. 
More broadly applicable is the arteriovenous loop that was first described by Erol 
and Spira in 1979. This technique was further developed and is still under 
investigation today. The AV loop is an in vivo model of axial vascularization and 
was successfully applied in small as well as large animals [106–108]. 
The AV loop can be used to vascularize various tissues and materials by placing 
them in close vicinity to a prominent vessel of adequate size in a so called 
isolation chamber in uninjured areas of the host’s body. The chamber creates 
some degree of autonomy of the created biovascularized neotissue graft [109]. 
Historically, the use of the AV loop in the context of bone regeneration focused 
on osteogenesis while the aspect of vascularization within bone was investigated 
subsequently. In a large animal study the successful employment of the methods 
of AV loop graft generation in sheep is presented [106]. It is demonstrated that 
the natural diffusion range could be increased in bone substitute materials such 
as TCP or hydroxyapatite in granular form as well as in solid form of relevant 
dimensions [110]. An increase in perfusion density was observed for 12 weeks 
by MRI before the endpoint analyses. Vascularization increased by sprouting 
from the main vessel of the AV loop. Limitations lie in the formation of new bone 
material, which could not be confirmed by histological means in this configuration. 
Additionally, the feasibility of the procedure was demonstrated in standard 
surgical context. The method got refined further by investigating the effect of the 
combination of intrinsic and extrinsic vascularization within the vascularization 
chamber [107]. The difference in both setups is the isolation chamber which was 
accessible by the surrounding tissue through perforation of the titanium chamber, 
so that vascularization was possible along the AV loop utilized (intrinsic 
vascularization) as well as through the surrounding area. The exclusively intrinsic 
vascularization was achieved by a Teflon chamber that allowed no external 
access except for the arteriovenous vessel that was intruded into the chamber. 
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The joint mechanisms of intrinsic and extrinsic vascularization proved to be 
superior to their single capacities [107]. An early clinical attempt of vascularizing 
a bone graft in human host tissue was the implantation of a mandibular bone graft 
for the restoration of the lower jaw. For in vivo vascularization, the graft consisting 
of bovine derived bone mineral was mixed with recombinant human BMP-7 and 
bone marrow aspirate. This method avoided creating a second site bone damage 
but caused donor-site morbidity in the latissimus dorsi muscle that served as a 
basis for graft vascularization [111]. Further clinical applications of the AV loop 
technique were described for a tibial defect and a large bone defect in the wrist 
due to carcinoma removal and it could contribute to the healing of those defects 
that previously did not heal without further intervention. The technique was 
modified in a way that the AV loop was created directly in the defect site, 
rendering a donor site redundant and thus, eliminating a major issue at least for 
specific cases since not all areas are eligible for this procedure [112]. 
 
1.4.3 Naturally derived decellularized scaffolds 
Native bone as it is used in autologous bone transplants is the golden standard 
for the treatment of large defects. The critical disadvantages of this approach can 
be controlled by the use of allogenic or xenogenic bone that has been 
decellularized. Among others, an important factor for the osteoconductive effect 
of materials used for bone regeneration is the micro- and macrostructure, e.g. the 
pore shape and size, the geometry as well as micropores and roughness of the 
surface [113]. All of these aspects can be utilized by decellularizing bone 
harvested from allogenic or xenogenic sources and thus overcoming the 
disadvantage of limited availability. During the essential removal of all cellular 
components, the bone extracellular matrix also loses many of its biologically 
active signals [114] while it still remains a potent biomaterial. A reintroduction of 
cues facilitating bone regeneration is possible via seeding decellularized bone 
with autologous cells or the addition of growth factors and thus, restoring a great 
deal of regenerative potential. 
Decellularized vascular structures are a promising component of the tissue 
engineering approach at supporting cells and tissues of a regenerative implant 
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that exceeds the dimensions that can be supported by diffusion alone with 
adequate amounts of nutrition and oxygen. Decellularized tissues are composed 
of a biocompatible extracellular matrix that naturally possesses mechanical 
properties suitable for the application of the intended purpose. The extracellular 
matrix itself can have a critical role in the regeneration of different tissues and 
additionally, it can be reseeded with human primary cells of endothelial linage to 
restore functionality of a vessel system that is capable of providing nutrition for 
other cell types in coculture. An example is the reintroduction of microvascular 
endothelial cells into the vascular structures of decellularized porcine jejunum of 
the small intestine as the so-called “biological vascularized scaffold” (BioVaSc-
TERM®) that is also one component of this thesis [115]. The repopulation of the 
vessel system of such a scaffold with endothelial cells reduces the probability of 
thrombus formation and the calcification of vessels [116]. The reseeded vascular 
structures can be dynamically perfused in specifically designed bioreactor 
systems in order to preserve the characteristics of differentiated endothelial cells 
or to initiate the differentiation of endothelial progenitor cells by applying shear 
stress [117]. It was shown that such a vascular graft could support survival of 
three-dimensional tissue of considerable size. A prevascularized scaffold of this 
type was filled with hepatocytes in the former lumen and a complex, structured 
liver-like tissue was formed. It was supported by capillaries sprouted from existing 
small vessels of the wall of the jejunum into the lumen [118].  
In orthopedic surgery, decellularized matrices in the shape of demineralized bone 
matrices (DBM) are a commonly used bone substitute material for filling defects. 
Donors of the bone are usually of bovine origin. During preparation of the 
demineralized matrix, soft tissue, blood, lipids are removed before acid 
demineralization. The result is a mixture of collagen type I, IV and X together with 
non-collagenous proteins, including BMP [119, 120]. The application of the matrix 
often takes place cell free but there are also experiments with previous cell 
seeding [120]. 
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1.5 Growth factors and the special role of BMP 
Bone morphogenetic proteins (BMPs) hold a prominent position in bone 
regeneration for their very efficient induction of bone formation. The following 
chapter addresses the BMPs’ attributes, their capabilities in bone regeneration 
and clinical limitations that explain why they are not a cure-all despite their 
excellent qualities. BMPs are members of the transforming growth factor TGF-
beta superfamily and are capable of differentiating mesenchymal stem cells into 
osteoblasts and thus form bone in targeted area. They influence and control 
differentiation, proliferation, state of maturation of a number of cells and they 
interact with other regulatory factors [121]. When BMPs interact with the surface 
receptor of a mesenchymal a complex cascade, which results in signals to the 
cell nucleus that induces the upregulation of gene expression that results in the 
production of molecules responsible for cartilage or bone formation. BMPs 
exerting a significant osteogenic activity are BMP-2, 4, 5, 6, 7, and 9 [122, 123]. 
BMP-2 and 7 have been studied intensively and are under investigation in human 
clinical trial especially targeting fracture healing and spinal fusions [124]. In the 
course of a number of successful applications of BMP-2 in clinical settings and 
with a magnitude of supporting research, it was rapidly becoming a frequent 
element of spinal surgeries in the USA since 2002 [125]. The success of 
recombinant human BMP-2 led to the approval for the use in human surgery by 
the FDA [126]. While the approval referred to the specific use of BMP in 
combination with a carrier matrix in a specific setting, the approval also inspired 
an extensive off-label use in clinical application. This means the application of 
pharmaceutical drugs for an indication different from the approved one or in 
unapproved dosages, age groups or routes of administration [127]. To date, there 
is no approval for a BMP-7 application for the use in human surgery.  
While the main attribution of BMPs is the formation of bone, its effects are not 
limited to that. It is able to trigger fat formation as well as adipogenesis in different 
environments [128, 129]. Additionally, it affects the expression of inflammatory 
cytokines and tumor necrosis factor TNF-α as well as receptor activator of nuclear 
kappa-B ligand (RANKL) that can elicit osteoclast activity. The sheer range of 
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effects that BMP-2 can have immediately suggest that clinically relevant 
reactions, apart from the desired bone formation, can be the result. 
An obvious side effect of BMP-2 as potent factor for bone induction is ectopic 
bone formation. BMPs can differentiate a range of cell types and thus a leakage 
of BMP during surgery leads to bone formation also in an environment of 
fibroblasts[130], myoblasts, adipocytes or chondrocytes [130–133]. The rate for 
ectopic bone formation in surgeries with BMP application was 70.1 % while the 
respective rate without BMP was 12.9 % [134]. Ectopic bone formation can be 
asymptomatic while in other settings can be a risk in the immediate vicinity of the 
spinal canal [135].   
It is well-known that BMP-2 can induce osteoclast activity especially  in 
cancellous bone [136]. A study that aimed at highlighting previously unreported 
incidents occurring alongside the use of BMP in clinical application during spine 
fusion reported a 69 % incidence rate for bone resorption. The study was based 
on the evaluation of CT images and states a patient selection bias due to the fact 
that CT scan are usually only performed on patients who experience 
complications postoperatively [137]. The results were confirmed in another study 
[138] and while the final results of the operative procedures indicate good fusion 
rates, it is demonstrated that especially during the early phase of resorption, 
osteolytic defects can occur due to the use of BMPs and should be subject to 
consideration during bone grafting. 
While local and systemic infections are generally a possible side effect of invasive 
procedures, the incident rate for delayed wound infections increased 3-fold in 
lumbar fusion surgeries [129] and 5-fold in anterior/posterior surgeries when BMP 
was applied [139]. Similarly, the general wound complication rate increased from 
18 % to 31 % in the BMP treatment group as compared to the control group [140]. 
Altogether, the use of BMP holds significant advantages in treatment of bone 
defects. Yet, its versatile nature and many modes of effect require thoughtful use 
and a clearly defined application profile in order to prevent any of the possible 
side effects. Therefore emerges the urgent necessity of approval of BMP use for 
very specific clinical settings by the cognizant authorities. 
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1.6 Animal models 
In bone, a critical size defect is defined as the smallest defect size that does not 
heal during the lifetime of an organism. In many scenarios the term critical size 
defect is accepted whether or not it is known if the defect is of the smallest size 
because the end of an experiment is most of the time determined by the endpoint 
rather than the natural lifespan of an organism [141]. The development of an 
effective bone regeneration implant is dependent on a relevant animal model that 
is able to expose the capabilities and limitations of the designated implant. Within 
the wide range of available animal models, the choice should be made for those 
with the general attributes of allowing for reproducibility, low morbidity and 
mortality until the end of the experiment. More specifically in the bone 
regeneration investigation the size should be comparable with human defects as 
well as the expected strain in order to gain information and to be able to assess 
the suitability and practicability if the procedures were projected onto human 
patients/comparability with the human clinical setting.  
 
1.7 Translation of research into clinical application 
The ultimate goal of research in the field of regenerative medicine is the approval 
for human use in order to treat diseases and functional dysfunctions of the human 
body. Comprehensive regulations apply in order to ensure patient safety for the 
permission to manufacture Advanced Therapy Medicinal Products (ATMPs) 
intended for human use. ATMPs include gene therapy, cell therapy and tissue 
engineered products as well as combinations of ATMPs and medicinal devices 
[142].  
 In Europe, the regulation of ATMPs is centralized and ensures a comparable 
assessment of quality, harmlessness and efficacy of pharmaceuticals.  ATMPs 
are controlled by the regulation 1394/2007, which introduces additional 
provisions to those laid down in Directive 2001/83/EC. Those are technical 
requirements, in particular the type and amount of quality, preclinical and clinical 
data necessary to demonstrate the quality, safety and efficacy of the product. 
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Due to the highly specific requirements, those aspects need to be established 
specifically for tissue engineered products in regulation 1394/2007. Centralized 
ATMP approvals are coordinated by the European Medicines Agency involving 
an expert committee, the Committee for Advanced Therapies (CAT), which was 
installed as official counselor responsible for judging the quality, safety and 
efficacy of each ATMP. Its recommendations are passed on to the Committee for 
Medicinal Products for Human Use (CHMP). Finally, the European Commission 
(EC) decides on the issuance of the permission for a manufacturing authorization 
based on the CHMP’s advice [142, 143].  
For the approval of ATMPs, there is an exception regulation that allows national 
approvals. The prerequisites are non-routinely production following specific 
quality standards in a specialized institution for patient care in the member state. 
The liability of the treatment is accepted by a physician on individual prescription.  
According to the German drug law (AMG) § 4b par. 3, ATMPS are object to 
approval by the Paul-Ehrlich-Institut (PEI), which ensures the demonstration 
quality, efficacy and harmlessness during the authorization process. 
The quality standards that apply to nationally approved ATMPs are the same as 
on European level. In order to conform with the required quality standards the so-
called good manufacturing practices (GMP) have to apply [142].  
The GMP guidelines postulate a quality management system including standard 
operating procedures, qualified personnel, GMP-compliant facilities and 
equipment. Quality control, handling of complaints and self-audits are additional 
aspects. These are installed with the aim of avoiding contaminations during the 
production and ensuring continuous and reproducible quality and complete 
traceability [144].
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1.8 Aim of the thesis 
This thesis addressed the following clinically relevant aspects of bone grafting: 
The production of a bone graft using minimally invasive methods, 
prevascularization based on the BioVaSc-TERM® in order to allow for an implant 
covering critical size defects and testing the regenerative potential thereof in an 
appropriate animal model. Additionally, the development of a mobile incubator 
system approached the transportation of the complex implant from the 
manufacturing site to the clinical site over a long distance. The whole 
developmental procedure considered GMP-conformity aspects for the option of 
rapid translation into clinical application. 
The identification of suitable cell sources is crucial for the aim of a minimally 
invasive concept of implant construction. Mesenchymal progenitor cells as well 
as endothelial progenitor cells both fulfill the requirements of being readily 
accessible, circumventing the problematic nature of donor site morbidity, and a 
functionally suitable choice of cells. Their high proliferation capacity and their 
ability to facilitate angiogenesis, bone formation in a synergistic fashion 
predestinates their employment in bone tissue engineering.  
The BioVaSc-TERM®, a naturally derived scaffold with vascular structures 
reseeded with endothelial progenitor cells, provides the basis for the 
vascularization of the implant, while ß-tricalcium phosphates seeded with 
mesenchymal progenitor cells are the mineral and cellular foundation for bone 
formation. 
The resulting construct is a complex implant that requires specialized equipment 
for transportation from the manufacturing site to the clinical site. An issue that is 
dealt with by the design of a mobile incubator and bioreactor that provides a 
controlled environment and physiological stimuli for the implant. 
The hypothesis that the manufactured implant is capable of inducing bone 
formation by providing effective cell delivery and survival due to vascularization 
was tested in vivo in sheep animal models.
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Table 2: Laboratory equipment 
Equipment or device Manufacturer 
Accu-jet® pro pipettor Brand, Wertheim (GER) 
Analytical balance Kern, Balingen-Frommern (GER) Sartorius, Göttingen (GER) 
Aspiration device Integra Biosciences, Fernwald (GER) 
Autoclaves: 
Tecnoclav 
Table-top autoclave 
Varioclav 
 
Biomedis, Giessen (GER) 
Systec, Wettenberg (GER) 
H+P, Hackermoos (GER) 
Bioreactor Weckert Labortechnik, Kitzingen (GER) 
Blocking station: EG1150H Leica, Wetzlar (GER) 
Cassette printer: VCP5001  Vogel Medizintechnik, Gießen (GER) 
Cell incubator Haraeus: BBD6220  
37 °C, 5 % CO2 
Thermo Fisher Scientific, Dreieich 
(GER) 
Centrifuges: 
Multifuge X3R 
 
Centrifuge 5417R 
Centrifuge 5424 
 
Thermo Fisher Scientific, Dreieich 
(GER) 
Eppendorf, Hamburg (GER) 
Eppendorf, Hamburg (GER) 
Cold-storage room, 4 °C Genheimer, Höchberg (GER) 
Cryostat: CM 1850 UV Leica, Wezlar (GER) 
Digital camera Canon, Krefeld (GER) 
Dish washer Miele, Gütersloh (GER) 
Drying oven Memmert, Schwabach (GER) 
Electrospinning apparatus Department of Functional Materials, Würzburg (GER) 
Embedding station: Microm STP 120 Thermo Fisher Scientific, Dreieich (GER) 
Freezer: 
-80 °C 
-20 °C 
 
Kendro, München (GER) 
Liebherr, Biberach a.d. Riss (GER) 
Freezing container “Mr. Frosty” VWR, Darmstadt (GER) 
Fume hood Prutscher Laboratory Systems, Neudörfl (AUT) 
Hot air sterilizer Memmert, Schwabach (GER) 
Ice machine: AF-80 Scotsman, Milan (I) 
Imaging station: FluorChem Q Biozym Scientific GmbH, Hessisch 
Oldendorf (GER) 
Immersion thermostat for water bath Lauda, Lauda-Königshofen (GER) 
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Equipment or device Manufacturer 
Laminar air flow cabinet: Safe 2020 Thermo Fisher Scientific, Dreieich 
(GER) 
Liquid nitrogen storage tank: MVE 
815 P-190 
German-cryo, Jüchen (GER) 
Magnetic stirrer: 720-HPS VWR, Darmstadt (GER) 
Micro-plate reader: Tecan Infinite 
M200 
Tecan, Crailsheim (GER)  
Microscopes:  
Axiovert 40C 
Biorevo BZ-9000 
Evos AMG 
Scanning electron microscope Zeiss 
DSM 940A 
Zeiss, Oberkochen (GER) 
KEYENCE, Neu-Isenburg (GER) 
Life technologies, Darmstadt (GER) 
Zeiss, Oberkochen (GER) 
Multi-Channel Pipette Plus Eppendorf, Hamburg (GER) 
Multistep pipette: Multipipette M4 Brand, Wertheim (GER) 
Neubauer cell counting chamber Hartenstein, Würzburg (GER) 
Orbital shaker NeoLab, Heidelberg (GER) 
Paraffinized tissue floating bath 1052 Medax, Kiel (GER) 
pH meter Mettler Toledo, Giessen (GER) 
Pipette tamping machine BellCo Glass Dunn, Asbach (GER) 
Pipettes: 
0.5–10 µl, 10–100 µl, 100–1000 µl 
Eppendorf, Hamburg (GER) 
Power supplies: EV202, EV243 PeqLab Biotechnology, Erlangen 
(GER) 
Rocking platform shaker NeoLab, Heidelberg (GER) 
Roller mixer Hartenstein, Würzburg (GER) 
Safety cabinet: Safe 2020 Thermo Fisher Scientific, Dreieich 
(GER) 
Slide printer: VSP 5001 Vogel Medizintechnik, Gießen (GER) 
Sliding microtome: SM 2010R Leica, Wetzlar (GER) 
Rotary Microtome RM 2255 Leica, Wetzlar (GER) 
Steamer “Multi Gourmet” Braun, Kronberg (GER) 
Thermomixer comfort Eppendorf, Hamburg (GER) 
Vortex Genie 2 Scientific Industries, INc., NY (USA) 
Water bath Memmert, Schwabach (GER) 
Water purification system Millipore, Schwalbach (GER) 
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Table 3: Disposables 
Disposable material Manufacturer 
Aluminum Foil  Carl Roth GmBH, Karlsruhe (GER)  
Catheter Introcan W 
14 G, 18 G, 20 G,  
B. Braun Melsungen AG, Melsungen 
(GER)  
Cell Culture Flasks: 25 cm², 75 cm², 
150 cm²  
TPP, Trasadingen (GER)  
Cell Culture Multiwell Plates: 6 well, 
12 well, 24 well, 96 well  
TPP, Trasadingen (GER)  
Cell culture plates 145 x 20 mm, 94 x 
15 mm, 60 x 15 mm, 35 x 10 mm 
TPP, Trasadingen (GER) 
Centrifuge Tubes: 15 ml, 50 ml  Greiner Bio-One, Frickenhausen 
(GER)  
Chamberslides: 8 well, Glass  Nunc, Wiesbaden (GER)  
  
Combitips Plus: 0.5 ml, 1 ml, 2.5 ml, 
5 ml  
Eppendorf, Hamburg (GER)  
Cover Slips for Object Slides: 24 x 
60 mm  
Menzel-Glaser, Braunschweig (GER)  
Cryo Tubes: 1.8 ml  Nunc, Wiesbaden (GER)  
Dako Pen  Dako, Hamburg (GER)  
Disposal Bags  Hartenstein, Wuerzburg (GER)  
Disposable microtome blades, type 
A35  
 
 
pfm medical, Cologne (GER) 
Easyflex+ empty bag sterile Macopharma, Tourcoing (FR) 
Gloves:  
Latex  
Nitrile  
 
Cardinal Health, Kleve (GER)  
Shield scientific,  BENNEKOM (NL) 
Grease Pencil  Dako, Hamburg (GER)  
Monovette blood collection tubes Sarstedt, Nümbrecht (GER) 
Object slides Menzel, Braunschweig (GER) 
Parafilm R, M  Carl Roth, Karlsruhe (GER)  
Pasteur Pipettes  Brand, Wertheim (GER)  
PCR Tubes  Biozym Scientific, Oldendorf (GER)  
Petri dishes: 145 x 20 mm, 94 x 
15 mm, 60 x 15 mm, 35 x 10 mm 
Greiner Bio-One, Frickenhausen 
(GER)  
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Disposable material Manufacturer 
Pipette Tips:  
0.5 – 10 µL, 10 – 100 µL, 100 - 
1000 µL  
Eppendorf, Hamburg (GER)  
Pump tubing Ismatec, Wertheim-Mondfeld (GER) 
Reaction Tubes: 1.5 mL, 2.0 mL  Sarstedt, Nümbrecht (GER)  
Scalpel Blades, rounded  Bayha, Tuttlingen (GER)  
Septophag Disposable Bags Porod, Frauenhofen (AUT)  
Diameter 50 mm, Pore Size 0.2 µm  Sartorius Stedium Biotech, 
Goettingen (GER)  
Sewing Thread Silkan 4/0 10x45 B. Braun, Melsungen (GER) 
Syringes: 5 ml, 10 ml, 20 ml, 50 ml  BD Biosciences, Heidelberg (GER)  
Tygon™ Sanitary Silicone Tubing 
Formula 3350 
Saint-Gobain,  Courbevoie (FR)  
Weighing Dish  Hartenstein, Wuerzburg (GER)  
 
Table 4: Laboratory material 
Laboratory material Manufacturer 
Beakers:   
1 L, 500 mL,  250 mL 
 
Schott, Mainz (GER) 
Centrifuge Tubes Rack  NeoLab, Heidelberg (GER) 
Cold Protection Gloves  VWR, Darmstadt (GER) 
Cover slips Menzel-Gläser, Braunschweig 
Female Luer Lug Style to 200 Series 
Barb, 1/8" (3.2 mm) 
Norson Medical, Fort Collins (USA)) 
Female Luer Lug Style Tee Norson Medical, Fort Collins (USA) 
Female Luer Thread Style with 5/16" 
Hex to 1/4-28 UNF Thread 
Norson Medical, Fort Collins (USA) 
Funnel  Hartenstein, Würzburg (GER) 
Glass cannula Weckert, Kitzingen (GER) 
Glass Cuvette with Lid: 
110 x 90 x 80 mm  
Mercateo, Munich (GER) 
Glas lid, 10 cm diameter Gaßner Glastechnik, Munich (GER) 
Glass Pipettes: 5 ml, 10 ml, 25 ml, 50 
ml 
 Brand, Wertheim (GER) 
Laboratory Bottle:   
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Laboratory material Manufacturer 
1 L, 250 ml, 100 ml, 50 ml  Schott, Mainz (GER) 
Laboratory glass bottle (Schott, GER) 
provided with custom glass tube 
connection 
Weckert, Kitzingen (GER) 
Male Luer Integral Lock Ring to 200 
Series Barb, 1/8" (3.2 mm) 
Norson Medical, Fort Collins (USA) 
Male Luer Integral Lock Ring Plug, 
Closed at Grip 
Norson Medical, Fort Collins (USA) 
Magnetic Stirring Bar Retriever  Hartenstein, Würzburg (GER) 
Needlefree Swabable Valve Female 
Luer to Male Luer Lock 
Norson Medical, Fort Collins (USA) 
Object Slide Racks: Glass, Stainless 
Steel  
Mercateo, Munich (GER) 
Protective Goggles  NeoLab, Heidelberg (GER) 
Reaction Tubes Rack  NeoLab, Heidelberg (GER) 
Surgical Knife Bayha, Tuttlingen (GER) 
Spatula  VWR, Darmstadt (GER) 
Spoon Spatula  Hartenstein, Würzburg (GER) 
Spray Flask (Ethanol, 70 %) Hartenstein, Würzburg (GER) 
Stainless Steel Casting Moulds for 
Embedding Tissue: 24 x37 x9 mm 
Labonord, Moenchenglattbach (GER) 
Straight Through Tube Fitting with 
Classic Series Barbs, 1/8" (3.2 mm) 
Norson Medical, Fort Collins (USA) 
Sterile Filter (Attachement for 
Laboratory Bottles)  
Hartenstein, Würzburg (GER) 
Tweezers  Assistent, Sondheim (GER) 
Volumetric Flasks with Plug: 1 L, 2 L  Schott, Mainz (GER) 
Y Tube Fitting with 200 Series Barbs, 
1/8" 
Norson Medical, Fort Collins (USA) 
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Table 5: Chemicals 
Chemical Manufacturer Order number 
2-Propanol  Carl Roth, Karlsruhe 
(GER) 
9866.6 
3-[(3-Cholamidopropyl) 
dimethylammonio]-1- 
Propanesulfonate  
(CHAPS) 
Merck, Darmstadt 
(GER) 
220201-1KG  
Acetic acid (100 %) Carl Roth, Karlsruhe 
(GER) 
6755.2 
Acetone (≥ 99,5 %) Carl Roth, Karlsruhe 
(GER)  
5025.5 
Acetylated low density 
lipoprotein 
Thermo Fisher 
Scientific, Dreieich 
(GER) 
L3484 
Acrylamide (30 %)  Carl Roth, Karlsruhe 
(GER)  
A124.2 
Agarose  AppliChem, Darmstadt 
(GER) 
A2114/CA50  
Albumine Fraction V (BSA)  Carl Roth, Karlsruhe 
(GER)  
T844.2 
Alcian blue  Sigma-Aldrich, Munich 
(GER)  
A3157-10G/DAL1100 
Amphotericin B Gibco, Darmstadt 
(GER) 
15290-026 
Antibody diluent Dako, Hamburg (GER) S302283 
Calcium Chloride (CaCl2)  VWR, Darmstadt 
(GER)  
1.02391.1000 
Citric Acid VWR, Darmstadt 
(GER)  
1.00244.1000 
Collagenase Roche, Mannheim 
(GER) 
11213865001 
Collagenase I Worthington 
biochemical, USA 
LS004196   
Collagenase II  LS004176 
DAPI Fluoromout-GTM  SouthernBiotech, 
Birmingham (USA)  
SBA-0100-20 
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Chemical Manufacturer Order number 
Deionized Water  University Hospital, 
Wuerzburg (GER) 
 
Descosept Seidel medipool, 
Reichertshofen (GER) 
506125 
Dimethyl sulfoxide 
(DMSO)  
Sigma-Aldrich, 
Schnelldorf (GER)  
D2438-50ML 
Donkey Serum  Sigma-Aldrich, 
Schnelldorf (GER)  
D9663-10ML 
DNase I, from bovine 
pancreas 
Roche, Mannheim 
(GER) 
10104159001 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
PAA, Colbe (GER)  G0001,3010 
Eosin Sigma-Aldrich, Seelze 
(GER)  
861006-25G 
Eosin Morphisto, Frankfurt 
Main (GER) 
10231 
Ethanol, absolut  Carl Roth, Karlsruhe 
(GER)  
9065.2 
Ethanol, denatured (96 %)  Carl Roth, Karlsruhe 
(GER) 
T171.2 
Ethylenediaminetetraacetic 
acid (EDTA – Na2 *2 H2O) 
Sigma-Aldrich, Seelze 
(GER)  
E5134-1KG 
Fetal Calf Serum  Lonza, Cologne (GER)  Lot No.8SBO16 
Feulgen staining kit VWR, Darmstadt 
(GER) 
1.07907.0001 
Fuchsin S, acid fuchsin Chroma, Muenster 
(GER) 
1B-525 
Gelatine Sigma-Aldrich, Seelze 
(GER) 
48720-100G-F 
Gentamycin (10 mg /mL)  PAA, Colbe (GER)  P11-004 
Glycerol (86 %)  Carl Roth, Karlsruhe 
(GER)  
4043.1 
Glycine  AppliChem, Darmstadt 
(GER)  
A1067,1000 
H2O2, 30 %  Carl Roth, Karlsruhe 
(GER)  
8070.2 
Hematoxylin  Carl Roth, Karlsruhe 
(GER)  
3861.1 
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Chemical Manufacturer Order number 
Hematoxylin Morphisto, Frankfurt 
Main (GER) 
10231 
Hydrochloric acid (HCl; 
37 %, 1M)  
VWR, Darmstadt 
(GER)  
1.09057.1000 
Isoflurane  Cp pharma, Burgdorf 
(GER) 
 
Isopropyl  Carl Roth, Karlsruhe 
(GER)  
2316.5 
Iron hematoxyline, 
Solution A 
Chroma, Muenster 
(GER) 
2E-032 
Iron hematoxyline, 
Solution B 
Chroma, Muenster 
(GER) 
2E-052 
Magnesium Chlorite 
Hexahydrate (MgCl2 *6 
H2O)  
Carl Roth, Karlsruhe 
(GER)  
HN03.3 
Mounting Medium: 
Entellan  
Merck, Darmstadt 
(GER)  
1079600500 
Mounting Medium: Mowiol  Carl Roth, Karlsruhe 
(GER)  
0713 
Nuclear Fast Red  Merck, Darmstadt 
(GER) 
1.15939.0025  
Paraffin Carl Roth, Karlsruhe 
(GER)  
6642.6 
Paraformaldehyde (PFA)  AppliChem, Darmstadt 
(GER)  
A3813,1000 
Penicillin / Streptomycin 
(100x concentrated)  
PAA, Colbe (GER)  P11-010 
Phosphate Buffered Saline 
(PBS) with calcium and 
magnesium 
Sigma-Aldrich, Munich 
(GER) 
D8537-6x500ml 
Phosphate Buffered Saline 
(PBS) without calcium and 
magnesium 
Sigma-Aldrich, Munich 
(GER) 
D8662-6x500ml 
phosphotungstic acid, 5 % Merck, Darmstadt 
(GER) 
1005830100 
Potassium Chloride (KCl)  Merck, Darmstadt 
(GER)  
1049361000 
RBC Lysis Buffer Biolegend 420301 
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Chemical Manufacturer Order number 
Roti-Histofix 4 % Carl Roth, Karlsruhe 
(GER) 
P087.1 
Roticlear® Carl Roth, Karlsruhe 
(GER) 
A538.5 
Saffron Sigma-Aldrich, Munich 
(GER) 
S8381-5G 
Sodium Chloride (NaCl) Carl Roth, Karlsruhe 
(GER)  
HN00.3 
Sodium Deoxycholic Acid  Carl Roth, Karlsruhe 
(GER) 
3484.7 
Sodium dodecyl sulfate     
(SDS; 10 %)  
BioRad, Munich (GER)  161-0416 
Sodium Hydrogen 
Carbonate (NaHCO3)  
Carl Roth, Karlsruhe 
(GER) 
HN01.2 
Sodium Hydroxyde 
(NaOH) Pellets  
Carl Roth, Karlsruhe 
(GER)  
6771.3 
Sodium Pyruvate (100 
mM)  
Invitrogen, Darmstadt 
(GER)  
11360-039 
TGF-β1 Cell Signaling Danvers 
(USA) 
8915 
Tris  Carl Roth, Karlsruhe 
(GER)  
4855.1 
Triton-X 100  Carl Roth, Karlsruhe 
(GER)  
3051.2 
Trizma Hydrochloride  Sigma-Aldrich, 
Schnelldorf (GER)  
T5941-1KG 
Trypan Blue, 0.4 %  Sigma-Aldrich, 
Schnelldorf (GER)  
T8154-100ML 
Trypsin (0,5 % (10x) with 
EDTA, 4 Na) 
Invitrogen, Darmstadt  
(GER) 
18912-014  
Tween-20  VWR, Darmstadt 
(GER) 
 8.22184.0500 
Ultrapure Water Millipore, Schwalbach 
(GER) 
 
Xylenes Carl Roth, Karlsruhe 
(GER) 
 9713.3 
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Table 6: Cell culture media 
Medium Composition  
   
MSCGM 500 ml Lonza MSCGM Basal 
Medium 
 
EGM-2 500 ml 
 
25 ml 
2 ml 
5,0 µg 
500 µg 
Lonza EGM-2 Basal 
Medium 
FCS 
ECGS/H-2 
hEGF-5 
Hydrocortisone-500 
Vasculife 500 ml  
5 ng/ml 
50 µg/ml 
1 µg/ml 
2 % 
10 mM 
15 ng/ml 
5 ng/ml 
5 ng/ml 
0.75 U/ml 
Vasculife Basal Medium 
rh FGF basic 
Ascorbic Acid 
Hydrocortisone 
FBS 
L-Glutamine 
rh IGF-1 
rh EGF 
rh VEGF 
Heparin sulfate 
 
 
Table 7: Buffers and solutions for cell culture 
Buffer/Solution Composition  
   
0.05 % Trypsin/EDTA working 
solution 
10 % (v/v) 
 
Trypsin/EDTA stock 
solution 
in PBS-/EDTA solution 
CaCl2-solution (300 mM) 22.1 g 
500 ml 
 
 
CaCl2 
Ultrapure water 
sterile-filtered before use 
stored at 4 °C 
Collagenase (500 U/ml) 1.0 g 
436 ml 
 
 
Collagenase 
DMEM 
sterile-filtered before use 
stored at -20 °C 
Chondroitin-6-sulfate solution 25 mg 
5 ml 
 
 
Chondroitin-6-sulfate 
PBS+ 
sterile-filtered before use 
stored at 4 °C 
DAPI staining solution 0.1 µg/ml 
 
 
DAPI  
in PBS- 
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Buffer/Solution Composition  
prepared immediately 
before use 
Dispase (2 U/ml) 400 mg 
100 ml 
 
 
Dispase  
PBS- 
sterile-filtered before use 
stored at -20 °C 
Fluorescein diacetate (FDA) 
solution 
5 mg/ml 
 
 
FDA 
in acetone 
stored at -20 °C 
Fibronectin stock solution  0.5 mg/ml 
 
 
Fibronectin lyophilisate 
in ultrapure water 
sterile-filtered  
Fibronectin working solution (50 
µg/ml) 
10 % (v/v) 
 
Fibronectin stock 
solution 
in PBS+ 
Gel neutralization solution (GNL) 7.5 ml 
2.5 ml 
7.5 ml 
232.5 ml 
 
 
3 M HEPES 
Chondroitin-6-sulfat-
solution 
FCS 
2 x DMEM 
sterile-filtered 
stored at 4 °C 
3M HEPES solution 7.15 g 
10 ml 
 
HEPES 
PBS-, 
sterile-filtered  
MTT reagent 3 mg/ml 
 
 
 
MTT  
in PBS+ 
sterile-filtered  
Stored at -20 °C 
MTT solution 1 mg/ml 
 
 
MTT reagent  
in PBS+ 
Prepared immediately 
before use 
PBS-/EDTA solution 0.5 ml 
500 ml 
EDTA 
PBS- 
Propidiumiodid (PI) solution  2 mg/ml 
1 ml 
 
PI 
in PBS+ 
Stored at -20 °C 
PI/FDA solution 1 µl 
9 µl 
990 µl 
FDA solution 
PI solution 
PBS+ 
Red Blood Cell Lysis Buffer 10 % (v/v) RBC Lysis Buffer stock 
solution in purified water 
WST solution 1 mg/ml WST reagent in PBS+ 
Prepared immediately 
before use 
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Table 8: Chemicals and Solutions for Histology and Immunohistochemistry 
Chemical/Solution Composition  
Acetic acid, 3 % 3 % (v/v) 100 % acetic acid 
in deionized water 
Stored at RT  
Acetic acid, 0.5 % 0.5 % (v/v) 100 % acetic acid 
in deionized water 
Stored at RT  
Alkaline alcohol 
 
10 mL 
90 mL 
Ammonium hydroxide 
96 % Ethanol 
Stored at RT 
Alcian blue, 1 % 10 g / L Alcianblau 8GX 
In deionized water 
Stored at RT 
Alcian blue (used for 
Pentachrome staining) 
1 g 
1 mL 
Alcianblau 8GX 
100 % acetic acid 
In deionized water 
Stored at RT 
Alizarin Red S working solution  
1 % 
Alizarin Red S 
Ammonia 
Brilliant crocein- acid fuchsin, 
solution A 
 
0,1 g 
0,5 mL  
99,5 mL  
Brilliant Crocein R  
100 % acetic acid 
Deionized water 
Brilliant crocein- acid fuchsin, 
solution B 
 
0,1g 
0,5 mL  
99,5 mL  
Acid Fuchsin 
100 % acetic acid 
Deionized water 
Brilliant crocein- acid fuchsin, 
working solution 
 
80 % (v/v)  
20 % (v/v) 
Solution A 
Solution B 
Stored at RT 
Citrate buffer stock solution 
(10 x concentrated) 
42 g / L  
17.6 g / L  
 
Citric acid 
NaOH pellets 
in deionized water 
pH 6.0    Stored at 4 °C 
Citrate buffer working solution 10 % (v/v)  
 
Citrate buffer stock 
solution 
in deionized water 
Stored at 4 °C. 
H2O2, 3 % 10 % (v/v) H2O2 solution (10 %) 
in deionized water 
Prepared immediately 
before use 
HCl /EtOH ( used for H&E 
Staining) 
6.85 % (v/v) HCl, 1M 
in Ethanol (50% v/v) 
Stored at RT 
Iron hematoxylin, solution A 
 
1g  
100 mL  
Hematoxylin 
96 % Ethanol 
Stored at RT 
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Chemical/Solution Composition  
Iron hematoxylin, solution B 
 
2,48 g 
 
 
1 mL  
Iron(III)chloride 
hexahydrate (FeCl3 x 6 
H2O) 
Concentrated HCl 
Add 100 ml deionized 
water 
Stored at RT 
Iron hematoxylin, working 
solution 
50 % 
 
50 % 
Iron hematoxylin, 
solution A 
Iron hematoxylin, 
solution B 
Nuclear Fast Red 
 
5 g 
 
 
0.1 g 
Aluminum sulfate 
in 100 ml deionized 
water 
Nuclear fast red added 
Stored at RT. 
Oil Red O, working solution 0.5 g Oil Red O 
in 100 ml isopropyl 
alcohol  
mixed with purified 
water 6:4 prior to use 
PFA 4 % 40 g / L Paraformaldehyde 
in PBS- solution (solved 
at 60°C) 
pH 7.4 
Stored at RT. 
Pikrofuchsin 
 
15 mL 
 
100 mL 
1 % Fuchsin S, acid 
fuchsin 
Saturated aqueous 
Pikrin acid  
Resochin-Fuchsin Solution A 0.5 g 
1 g 
Fuchsin 
Resorchin 
In deionized water 
Resochin-Fuchsin Solution B 2 g 
10 mL 
Iron chloride  
Deionized water 
Rescohin-Fuchsin working 
solution 
5 % (v/v) 
5 % (v/v) 
90 % (v/v) 
Solution A 
Solution B 
HCl-Ethanol 
Saffron du Gatinais 6 g 
100 mL 
Saffron du Gatinais 
96 % Ethanol 
Stored in the dark at RT 
PBST, 0.05 M 100 mL 
    5 mL 
900 mL 
PBS stock 10x 
Tween-20 (0.5 % v/v) 
Deionized Water 
Stored at RT. 
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Chemical/Solution Composition  
Phosphate buffered solution 
(PBS) stock, 0.5 M, 10x 
concentrated 
191.00 g 
 
PBS powder 
ad 2 L ultrapure water 
pH 7.2 
Stored at RT. 
Triton-X Permeabilizing Solution  
 
0.2 % (v/v) in 
0.05 M 
 
Triton-X 100 
TBS Buffer 
Stored at RT. 
 
 
Table 9: Research animals 
Animal Origin 
Deutsche Landschwein Rasse pigs Niedermayer, Dettelbach (GER) 
Tiroler Bergschaf Lehr- und Forschungsgut - Veterinary 
Medical University Vienna 
Merino sheep Medical Engineering Research 
Facility (MERF), Brisbane 
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 Methods 
 
3.1 Cell culture methods 
 
Sterile work was conducted in class II laminar flow benches. All solutions were 
sterile filtered before use if necessary. All material, except single-use items, were 
autoclaved or hot-air sterilized before use. If not otherwise stated, all cell culture 
media and solutions were warmed up to 37 °C in a waterbath before use. Culture 
of cells was performed in incubators with a relative humidity of 95 %, 5 % CO2 
and a temperature of 37 °C. 
 
3.1.1 Isolation of primary human cells 
3.1.1.1 Mesenchymal progenitor cells 
 
Primary human mesenchymal stem cells were isolated from spongy bone. 50 ml 
conical tubes were filled half with spongy bone and 20 ml of prewarmed PBS+ 
were added. The tube was closed and manually shaken thoroughly in order to 
liberate cells from the spongy bone. After 5 minutes of sedimentation, the 
supernatant was collected in a separate tube. The procedure was repeated until 
the spongy bone, that previously appeared red, became almost white in color. 
This was usually the case after 5 washing steps. The collected cell suspension 
was centrifuged for 5 minutes at 270 g and the supernatant was aspirated. The 
cell pellet was resuspeded in 25 ml of MSCGM and cells were counted by mixing 
50 µl of the cell suspension with 1 x lysis buffer 1:2 before the standard counting 
procedure. The buffer lysed the vast amount of red blood cells and allowed for 
the counting of the mononuclear cells isolated. Cell seeding took place in T150 
flasks at a cell density of 3 x 103 cells per cm2 and medium change took place 
twice a week. 
 
 
Methods 
38 
 
3.1.1.2 Microvascular endothelial cells 
 
Human microvascular endothelial cells were isolated from adult skin biopsies or 
from foreskin. Skin biopsies were placed in a Petri dish and rinsed with PBS+ 
three times before fat and connective tissue were removed with a scalpel. After 
surface estimation of the biopsies and cutting them into stripes of 2 – 3 mm, they 
were transferred into another Petri dish containing 10 ml of dispase. Wrapping 
the dish with parafilm® it was incubated at 4°C for 16 – 18 h overnight. The next 
day, the dermis was separated from the epidermal layer using tweezers. The 
dermis was collected in a Petri dish filled with 20 ml of PBS+. The PBS+ was then 
aspirated and replaced by Versene and samples were gently swayed. Following 
the removal of the Versene an incubation with 10 ml of 0.05 % trypsin/EDTA per 
every 6 cm2 of sample for 40 minutes achieved loosening of the tissue. The 
enzymatic reaction stopped after the addition of 1 % of FCS and the transfer of 
the dermal pieces into another Petri dish filled with prewarmed Vasculife medium 
followed. The actual liberation of cells from the tissue took place by squeezing 
the dermal stripes lengthways using tweezers and a scalpel. The procedure was 
repeated eight times from all sides. The resulting cell suspension was put through 
a strainer and collected in a 50 ml conical tube before centrifugation at 270 g for 
5 minutes. Subsequent to the resuspension of the cells in Vasculife they were 
seeded into T25 or T75 cell culture flasks at their specific seeding density 
(foreskin: 1.2 x 104 cells/cm²; adult skin: 4 – 5 x 104 cells/cm²). Medium change 
took place every 2 – 3 days. Cell morphology was observed during culture of 
endothelial cells. In case of a contamination with fibroblasts, the medium was 
aspirated and cells washed with PBS-. Versene was added for 5 – 10 min 
(0.15 ml/cm2) while observation under the microscope. As soon as fibroblasts 
began to round up, tapping of the flasks detached the fibroblasts from the surface. 
After aspiration of the Versene, washing of cells followed before adding fresh 
Vasculife. 
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3.1.2 Isolation of primary ovine cells 
3.1.2.1 Mesenchymal progenitor cells 
 
Ovine mesenchymal progenitor cells were isolated from bone-marrow aspirate. 
Bone marrow aspirate was mixed 1:2 with PBS- and 20 ml carefully layered over 
15 ml density gradient centrifugation medium prepared in a 50 ml conical tube. 
Subsequently, centrifugation at 800 g at room temperature followed for 20 
minutes. The centrifuge ran at low acceleration and without break. The resulting 
opaque layer containing the cells was transferred into a separate conical tube 
using a 5 ml pipette. Cells were washed with 35 ml of PBS-/EDTA and centrifuged 
at 800 g for 10 minutes. The supernatant was aspirated and the washing step 
repeated. The resulting pellet was resuspended in 10 ml of MSCGM and 
transferred into a T75 cell culture flask. The next day, after attachment of the 
cells, they were gently washed with PBS+ in order to remove residual erythrocytes 
and cell debris from the culture. Medium change took place twice a week. 
 
3.1.2.2 Endothelial progenitor cells 
 
Isolation of ovine endothelial progenitor cells was performed by density gradient 
centrifugation of peripheral whole blood using Histopaque®-1077 medium 
(Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany). Cells were centrifuged at 
400 g for 30 min. After two washing steps, the resulting cell fraction was seeded 
on standard cell culture surfaces with ECGM-2 medium (Promocell, Heidelberg, 
Germany). Surfaces were coated with 1 % fibronectin before. Medium change 
was performed twice a week. 
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3.1.3 Cell culture conditions  
3.1.4 Passaging of cells 
 
Cell expansion took place in cell culture flasks, passaged when confluence 
reached 80 – 90 %. To this end, the medium was aspirated and cells were 
washed with PBS-. Microvascular endothelial cells were then incubated with 
prewarmed PBS-/EDTA for approximately 10 minutes, the solution was aspirated 
when cells began to round up. The incubation with 0.05 % trypsin/EDTA was 
performed for 3 – 5 min followed by the addition of 1 % FCS to stop the enzymatic 
reaction. After a microscopic check, the cells were transferred into a 50 ml conical 
tube and centrifuged for 5 minutes at 270 g. Following the aspiration of the 
supernatant, the cell pellet was resuspended in appropriate cell culture medium 
and their number was determined. 
 
3.1.5 Cell counting and cell viability determination 
 
The Neubauer counting chamber and staining with trypan blue were used to 
count cells and determine viability. In the presence of trypan blue, viable cells 
appear colorless, while dead cells are blue. After detachment, an aliquot of cells 
was mixed 1:2 with 0.4 % trypan blue and the resulting solution was applied to 
the counting chamber. The number of viable and dead cells in all four quadrants 
of the chamber were counted.  
Viable cell number was calculated as follows: 
 =  × 10000 × 
 ×  
 
Total cell number was calculated as follows: 
 =  +	 × 10000 ×  ×  
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Viability was calculated as follows: 
	% = 	


	× 100	% 
CC cell count VCC viable cell count 
CCtot total cell count MVCC mean viable cell count 
MCCd mean dead cell count DFTB dilution factor trypan blue 
Vsusp volume of cell suspension V vitality [%] 
 
 
3.1.6 Freezing of cells 
Cells were frozen at a cell density of 1 x 106 cells/ml in their respective medium 
supplemented with 10 % FCS and 10 % DMSO. 1 ml of cells in their freezing 
medium was applied to cryo tubes before prompt placement into Mr Frosty 
freezing containers and storage at -80 °C for at least 24 h. Longtime storage took 
place at -180 °C in a liquid nitrogen tank. 
 
3.1.7 Thawing of cells 
 
Cryo conserved cells thawed at 37 °C in a waterbath before the transfer into a 15 
ml conical tube and resuspension in 9 ml prewarmed cell specific medium. After 
centrifugation for 5 minutes at 270 g, the supernatant was aspirated and the cell 
pellet was resuspended in fresh cell specific medium and cells were seeded into 
cell culture flasks. Medium aspiration 24 h later ensured removal of debris of dead 
cells and new medium was added. 
 
3.1.8 Differentiation of human and ovine mesenchymal stem cells 
 
In order to confirm the pluripotent nature of the MSC of human and ovine origin, 
their ability to differentiate was checked by the differentiation into the adipogenic, 
chondrogenic and osteogenic linage. 
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3.1.8.1 Adipogenic differentiation 
 
Differentiation of human mesenchymal stem cells into adipocytes  was achieved 
by culture of the cells in adipogenic differentiation medium. For this, 100,000 cells 
were seeded into each well of a permanox 4-well chamberslide. Cells were 
cultured in MSCGM containing 2 % FCS until a confluent monolayer was 
established. Then, the culture continued in adipogenic differentiation medium.  
 
Table 10: Composition of adipogenic differentiation medium 
Component Concentration 
DMEM  
FCS 10 % 
Dexamethasone 1 µM 
IBMX 500 µM 
Insulin 1 µg/ml 
Indomethacin 100 µM 
 
One chamber per chamberslide served as control and was cultured in MSGCM 
with 2 % FCS. Medium change took place three times a week over a duration of 
14 days. 
 
3.1.8.2 Chondrogenic differentiation 
For the chondrogenic differentiation, MSC were culture in pellets by seeding 2.5 x 
106 cells into a 15 ml conical tube with subsequent centrifugation at 270 g for 5 
minutes. 
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Table 11: Composition of chondrogenic differentiation medium 
Component Concentration 
DMEM  
FCS 10 % 
Ascobart-2-phosphate 50 µg/ml 
Dexamethasone 1 µM 
Pyruvate 100 µg/ml 
L-Proline 40 µg/ml 
ITS+1 1 5 
TGF-ß3 10 ng/ml 
 
TGF-ß3 was added right after the addition of medium. Cell pellets in the 
differentiation medium without TGF-ß3 served as control. Medium was changed 
twice a week for 21 days in total. 
 
3.1.8.3 Osteogenic differentiation 
Osteogenic differentiation was achieved by culture of MSCs in osteogenic 
differentiation medium. Initially, 100.000 MSCs were seeded into each well of 4-
well chamberslides in MSGCM with 2 %FCS. Upon the formation of a confluent 
monolayer, the medium was exchanged with osteogenic differentiation medium. 
 
 
Table 12: Composition of osteogenic differentiation medium 
Component Concentration 
DMEM  
FCS 10 % 
Ascobart-2-phosphate 50 µg/ml 
Dexamethasone 1 µM 
ß-Glycerophosphate 10 mM 
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The MSCs of one chamber were continually cultured in MSGM with 2 % FCS as 
a control. Medium change took place three times a week for a total duration of 
28 days. 
 
3.2 Generation of the cell-free biological vascularized scaffold 
BioVaSc-TERM® 
 
The biological vascularized scaffold (BioVaSc-TERM®) was generated from 
resected porcine jejunal segments including the associated supporting vessel 
system. Tissue harvesting from 2-year-old piglets (10 – 15 kg) was performed in 
compliance with the Guide for Care and Use of Laboratory Animals and approved 
by the local animal protection board. On explantation, the arterial and venous 
pedicles were cannulated and immediately perfused with 0.9 % NaCl solution in 
order to check venous return and to clean it from residual blood. Remnants were 
removed from the jejunal lumen and tissue was transferred into a pressure 
controlled bioreactor system for decellularization. The vascular structures and 
lumen were perfused with 500 ml 3.4 % sodium deoxycholate monohydrate at a 
pressure of 80 mmHg. Cell remnants were removed by perfusion with 1 liter 0.9 % 
NaCl solution. The scaffold was subsequently incubated with 250 ml 3.4 % 
sodium deoxycholate monohydrate overnight at 4 °C. The next day, vessel 
integrity of the scaffold was checked by perfusion with 2 ml of 0.1 % phenol red. 
In the following washing steps the BioVaSc-TERM® was perfused with 2 l of NaCl 
under constant pressure monitoring. DNA digestion was achieved by incubation 
overnight in 250 ml DNase solution. After the final washing steps of four times 
incubation in 250 ml 0.9 % NaCl, gamma irradiation was performed with a 25 kGy 
dose (BBF Sterilisationsservice GmbH, Rommelshausen, Germany). During the 
decellularization process samples of the solutions were taken in order to perform 
bile acid assay and measurement of endotoxin levels. After gamma irradiation, a 
small peripheral part of the BioVaSc-TERM® was taken for quality control 
(histology, DNA content measurement). Manufacturing protocols documented the 
process.  
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3.3 Generation of prevacularized bone implants 
 
For the seeding of the BioVaSc-TERM® with microvascular endothelial cells or 
endothelial progenitor cells and bioreactor system was employed. The reactor 
system consisted of a sealable glass bowl with two insertions that allowed the 
connection to silicone tubes that established connections to a reservoir bottle and 
a pressure bottle. The circuit contained pumping tubes that enabled the perfusion 
of the system with medium via peristaltic pumps. 
 
3.3.1 Seeding of BioVaSc-TERM® with microvascular endothelial 
cells 
 
The BioVaSc-TERM® was placed in 20 ml Vasculife medium at 37°C during 
detachment of mvECs and 5.0 x 106 cells were taken up in 5 ml Vasculife medium 
in a syringe that then was attached to the arterial pedicle and cells were slowly 
inserted. The scaffold was incubated for 3 h and seeded a second time with 
5.0 x 106 mvECs. After another 3 h of incubation the BioVaSc-TERM® was placed 
into the bioreactor system a perfused at 5 rpm (~ 5 ml/min) overnight. The next 
day, dynamic pressure conditions were established dynamically at 80 – 120 
mmHg, 1 Hz, using the bioreactor and incubator system. The culture continued 
for two weeks with two partial media changes per week (50 ml). At the end of the 
culture period, perfusion with 2 ml of 0.1 % phenol red demonstrated vessel 
integrity of the scaffold. 
 
3.3.2 Seeding of MSCs onto ß-TCP granules 
 
5 ml of ß-TCP granules were filled into each well of a 6-well plate. MSCs were 
detached and 2.5 x 106 cells were seeded onto the granules in 600 µl MSCGM 
per well. After 20 minutes of incubation at 37 °C the medium volume was 
increased to 4 ml so that the granules were covered. The culture period was 3 
days before the granules were combined with the BioVaSc-TERM®. 
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3.3.3 Combination of reseeded BioVaSc-TERM® and seeded ß-TCP  
 
If not stated otherwise, after 3 days of culture of the MSCs on TCP and 7 days of 
culture of the reseeded BioVaSc-TERM® both components were combined. One 
end of the BioVaSc-TERM®’s lumen was clamped while from the other end, the 
lumen was filled with cell-seeded granules using a spatula. Approximately 10 ml 
of granules filled the BioVaSc-TERM® before the combined culture continued for 
7 days. 
 
3.3.4 Prevascularized bone implantation in the ovine tibia 
 
The BoneVaSc-TERM® was brought into a critical-size tibia defect in sheep and 
sutured to the adjacent periosteum of the bony ends left and right from the defect. 
The defect was an excision of 3 cm of the tibia that was then stabilized with 
reconstruction plates. The plates were anchored with four screws proximally and 
three screws distally. The implantation was prepared as described: 
Propofol (15 cm3 at 1.0 mg/cm3) initiated anesthesia. Flunixin-Meglumin (50 
mg/ml, 2.2 mg/kg bodyweight) and Buprenorphine (0.01 ml/kg bodyweight) 
maintained premedication and analgesia. Pre-emptive administration of the drugs 
ensures multimodal pain therapy to control pain over 24 h after the surgery. 
Postoperative pain assessment every 8 – 10 h after surgery decided over 
Buprenorphine injections for up to 48 h. Antibiotics were administered 
approximately 8 h before surgery (Cefazolin 10 mg/kg). Additional doses followed 
at the time of the surgery, each day after surgery for 3 days. 
During surgery, animals were intubated with a 9 – 10 mm cuffed endotracheal 
tube while Propofol maintained anesthesia. Heart rate, oxygen saturation and 
end-tidal carbon dioxide levels were monitored continuously. 
 
3.3.5 Prevascularized bone implantation in the mandibular angle 
 
Before surgery, 1 mg Atropine  and 0.01 mg/kg Detomidin were administered as 
premedication before anesthesia. Anesthesia itself was initiated by 5 mg/kg of 
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2 % Propofol and 0.1 Fentanyl. After endotracheal intubation, anesthesia was 
maintained by Fentanyl 0.2 ml/kg/h, Tracrium 0.03 ml/kg/h and 2 % Propofol 
0.5 ml/kg/h. Antibiotic treatment was conducted with 2.0 g of Cefazolin. 
Postoperative analgesia included the administration of Buprenorphin (5 – 
10 µg/kg bodyweight) intravenously every six hours and Flunixin (2 mg/kg 
bodyweight) subcutaneously every 24 h. The second day after the surgery a 
Fentanyl containing patch was applied (100 µg/h) for 72 h. 
The surgical procedure was performed as follows: The skin of the sheep was 
shaved and disinfected in the operational area. Subsequently, the mandible was 
accessed by a submandibular approach. To this end, the skin was incised and 
the layers of subcutaneous tissue were dissected. The facial nerve and the 
submandibular vein were identified and conserved while elevating the periosteum 
exposed the inferior border of the mandible. The continuity defect was defined 
using a mold outlining the designated defect geometry in order to ensure the 
same defect in all animals. Before the creation of the defect, reconstruction plates 
were placed over the designated defect area and fixed with two screws on each 
side while they were bent to fit the individual geometry of the mandible. Following 
the adaption of the plates, the defect was created according to the performed 
definition using a piezo saw. Partial attachment of the plates together with a titan 
mesh followed the removal of the bone. The mesh protected the defect area and 
prevented prolapse of soft tissue around the defect. The BoneVaSc-TERM® was 
placed between the ends of the created defect and anastomosed to the facial 
artery and the corresponding vein using 7– 0 and 8 – 0 sutures. Visual inspection 
confirmed capillary patency of the vessel system before closure of the wound by 
repositioning and suturing muscles and skin. 
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3.4 Characterization 
 
3.4.1 Histology 
3.4.1.1 Fixation 
 
Before fixation, the medium of cells on cell culture surfaces was aspirated. 
Following, the cells or tissues were washed with PBS- and then fixed with 4 % 
PFA for 10 minutes at room temperature. Due to their thickness, tissues and 
collagen gels were fixed for at least 2 h to allow thorough infiltration of the tissue 
and proper fixation in the inner compartments.  
 
3.4.1.2 Paraffin embedding  
 
In order to create thin sections of tissues for further analyses, samples were 
embedded in paraffin. The BioVaSc-TERM® was dissected into smaller parts 
before paraffinization depending on the region of interest. 
Samples were put on embedding paper and transferred into labeled embedding 
cassettes. 1 – 2 h incubation in tap water ensured removal of residual PFA before 
placing samples into the embedding machine that automatically carried them 
through the following steps: 
Table 13: Paraffin embedding 
Time [h] Solution Function 
Over night 50 % EtOH  
 
Dehydration 
1 70 %  
1 90 % 
1 96 % 
1 Isopropyl alcohol I 
1 Isopropyl alcohol II 
1 Isopropyl alcohol/Xylene  
Alcohol removal 1 Xylene I 
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Time [h] Solution Function 
1 Xylene II 
1.5 Paraffin I  
Paraffin infiltration 1.5 Paraffin II 
 
Upon the finished process, tissue samples were cut into smaller pieces and 
placed into casting molds in a horizontal orientation to allow for longitudinal 
cutting later on. The molds were filled with molten paraffin in an embedding 
station and allowed to cool down until the paraffin completely solidified. Before 
the preparation of tissue sections of 5 µm, molds stayed on a cooling plate for at 
least 20 minutes to allow for more consistent sectioning using a sliding or a rotary 
microtome. Sections were placed on polysine adhesion microscope slides and 
straightened in a water bath at 37 °C. Sections were allowed to dry for at least 
2 h and directly processes or stored at 4 – 8 °C. 
In order to allow access of dyes to the prepared sections, the paraffin had to be 
removed and rehydrated by the process of deparaffinization. The following steps 
were performed manually by moving the object slides through cuvettes filled with 
the following solutions: 
Table 14: Deparaffinization 
Time [min] Solution Function 
10 Xylene I  
Deparaffinization 10 Xylene I 
Dip 3 times 96 % EtOH  
 
Rehydration 
Dip 3 times 96 % EtOH 
Dip 3 times 70 % EtOH 
Dip 3 times 50 % EtOH 
Sway until turbulence clears Purified water Washing 
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3.4.1.3 Technovit® 9100 embedding 
 
Technovit is a plastic embedding system based on methyl methacrylate and 
suitable for embedding hard tissues. 
Table 15: Technovit embedding 
Time [h] Solution Function 
2 4 % Formalin Fixation 
2 Purified water Hydration 
2 70 % EtOH Dehydration 
2 80 % EtOH 
2 96 % EtOH 
At least 2 Isopropyl alcohol I 
At least 2 Isopropyl alcohol II 
At least 2 Xylene 
At least 2 Xylene 
Overnight Xylene+Technovit  
Overnight Technovit+Hardener 1 Pre-infiltration  
Overnight at 4 °C Technovit+Hardener 1  
Overnight at 4 °C Technovit+Hardener 1+PMMA Infiltration 
Overnight at 4 °C Technovit+Hardener 1+ 
Hardener 2+PMMA+ 
Polymerization 
regulator 
Embedding 
 
During the protocol, samples were handled in 50 ml conical tubes. For the last 
step, samples were placed in polyethylene embedding molds. After desiccation, 
the molds were sealed and stored at 4 °C overnight. Semi-thin sections of 30 – 
50 µm thickness were created and placed on object slides. Sections were 
stretched with 50 % EtOH and a PVC film was applied. Slides were placed in a 
section press and stored under pressure at 50 °C overnight. In order to make 
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plasticized sections accessible for dyes, the following deplasticizing protocol was 
performed: 
Table 16: Deplasticizing 
Time [min] Solution Function 
2 x 20 Xylene  
 
 
Deplasticizing 
20 2-methoxyethyl acetate 
2 x 5 Acetone I 
2 x 5 Acetone II 
 Purified water Washing 
Samples were mounted with Mowiol®. 
 
3.4.1.4 Hematoxylin and eosin stain 
 
Hematoxylin and Eosin (H&E) staining is suitable method for assessing tissue 
morphology. It results in blue colors in acidic or basophilic structures as for 
example in the cell nucleus. Eosin in contrast results in red colorization in 
acidophilic structures of tissues or cells as for example plasma membrane 
proteins or collagens. Following deparaffinization and rehydration, the 
subsequent protocol was executed: 
Table 17: H&E staining 
Time [min] Solution Function 
6 Hematoxylin (Mayer) Staining of basophilic 
structures (e.g. cell 
nuclei) 
Sway until turbulence 
clears 
Purified water Washing 
5 Tap water Blueing 
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Time [min] Solution Function 
6 Eosin Staining of acidophilic 
structures (e.g. 
cytoplasm)  
Sway until turbulence 
clears 
Purified water Washing 
Dip 2 times EtOH 70 %  
 
 
Dehydration 
2 EtOH 96 % 
5 Isopropyl alcohol I 
5 Isopropyl alcohol II 
5 Xylene I 
5 Xylene II 
Samples were mounted with Mowiol®. 
 
3.4.1.5 Alcian blue 
 
Alcian blue was used to stain negatively charged sulfated proteoglycans in the 
chondrogenic matrix of the cell pellets created during the chondrogenic 
differentiation assay. 
Subsequent to deparaffinization, this staining protocol followed: 
Table 18: Alcian blue staining 
Time [min] Solution Function 
3 Acetic acid  
30 Alcian blue Staining of negatively 
charged glycosamino- 
and proteoglycans 
Sway until turbulence 
clears 
Purified water Washing 
5 Nuclear fast red Staining of nuclei 
Sway until turbulence 
clears 
Purified water Washing  
Methods 
53 
 
Time [min] Solution Function 
Dip 2 times 70 % EtOH  
 
Dehydration 
2 96 % EtOH 
5 Isopropyl alcohol I 
5 Isopropyl alcohol II 
5 Xylene I 
5 Xylene II 
Samples were mounted with Mowiol®. 
 
3.4.1.6 Alizarin Red S 
 
The osteogenic differentiated cells were analyzed with Alizarin Red S, a dye that 
stains dicalcium phosphates as they are present in the extracellular matrix of 
osteoblasts. The staining protocol is listed below: 
Table 19: Alizarin Red S staining 
Time [min] Solution Function 
Dip once PBS- Washing 
10 methyl alcohol, ice-cold Fixation 
Sway until turbulence 
clears 
Purified water Washing 
2 Alizarin Red S working 
solution 
Staining of dicalcium 
phosphates 
0.5 Hemalaun Staining of nuclei 
1 Tap water Blueing 
Samples were mounted with Mowiol®. 
 
3.4.1.7 Oil Red-O  
 
The  Oil Red-O staining verified the formation of lipid droplets in the adipogenic 
differentiation of MSCs. The azo dye is liposoluble and stains triglycerides 
produced by adipocytes.  
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Table 20: Oil Red-O staining 
Time [min] Solution Function 
Dip once PBS- Washing 
10 4 % PFA Fixation 
Sway until turbulence 
clears 
Purified water Washing 
5 60 % isopropyl alcohol  
10 Oil Red-O working 
solution 
Staining of lipid droplets  
Sway until turbulence 
clears 
Purified water Washing 
0.5 Haematoxylin Staining of nuclei 
1 Tap water Blueing 
 
3.4.1.8 Feulgen staining 
 
The Feulgen staining is a suitable method for investigating the degree of 
decellularization. This method results in red-purple stains for DNA and thus, gives 
information on DNA content in a tissue. It allows the detection of residual cells, 
fragments of cell nuclei or DNA in decellularized tissue. For a standardized 
decellularized matrix, it is important to show the absence of DNA in order to 
exclude any effects on cells seeded on the scaffold later on. 
  
3.4.1.9 Movat’s pentachrome staining 
 
Movat’s pentachrome is a staining method for the detection of connective tissue 
components. This method depicts cell nuclei as blue-black, glycosaminoglycans 
as blue, muscle tissue as red, elastic fibers and osteoid as red, collagen yellow, 
cartilage red and bone as yellow-orange staining. 
Methods 
55 
 
Table 21: Movat’s pentachrome staining 
Time [min] Solution Function 
10 Alcian blue Staining of negatively 
charged glycosamino- 
and proteoglycans 
5 Purified water Washing 
60 10 % alkaline alcohol Fixation  
5 Purified water Washing 
10 Hematoxylin Staining of basophilic 
structures (e.g. cell 
nuclei) 
1 Purified water Washing 
15 Tap water Blueing 
30 Brilliant crocein Staining of elastic fibers 
and cytoplasm  
Sway until turbulence 
clears 
0.5 % Acetic acid Washing 
 15.5 % Phosphotungstic 
acid 
Differentiation  
5 0.5 % Acetic acid Washing  
5 EtOH 96 % Rinsing  
5 EtOH 96 % 
60 Safron du gatinias Staining of mineralized 
bone and cartilage 
tissue 
4 EtOH 96 % Dehydration 
4 EtOH 96 % 
5 Xylene Clearing  
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3.4.2 Immunohistochemistry 
 
Immunohistochemistry is the analysis of tissue or cells with immunochemical 
methods as staining of cell or tissue structures with dyes linked with antibodies. 
There is direct staining with primary antibodies linked directly to marker.  
Additionally, there are indirect methods that direct a secondary antibody against 
the so-called fragment crystallizable region (Fc region) of the primary antibody. 
The secondary antibody carries a marker that can be a chromogenic substrate or 
fluorescent dye. In the second case, the method is called immunofluorescence. 
The principle of the method is based on the affinity of antibodies to specific 
epitopes of antigens on the surface or the inside of tissues or cells. Antibody and 
antigen stably bond while for the indirect method a secondary antibody 
additionally detects the primary antibody. The secondary antibody is conjugated 
with horseradish peroxidase (HRP) which can be made visible with substrates 
that are oxidized by the HRP. In case of 3,3'-diaminobenzidine (DAB) as a 
substrate, the result is a brown staining indicating the exact location of the 
targeted antigen. 
This method was applied to tissue sections and cells seeded on cell culture 
surfaces as for example well plates or chamberslides. Cells were fixed with 4 % 
PFA for 10 minutes at room temperature. Tissue was prepared as described 
above. Antigen-retrieval was performed heat-induced in a steamer. Citrate buffer 
at a pH of 6 was heated up to 100 °C in the steamer, slides were then incubated 
for 20 minutes. The following incubation steps were carried out in a humidity 
chamber at room temperature: 
 
Table 22: Immunohistochemistry 
Time [min] Solution Function 
10 3 % H2O2 Blocking endogenous 
peroxidase 
3 x 5 PBS-Tween Washing 
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Time [min] Solution Function 
60 Primary antibody 
solution 
Primary antibody 
3 x 5 PBS-Tween Washing 
10 Secondary antibody 
solution 
Secondary antibody 
3 x 5 PBS-Tween Washing 
2 DAB solution detection 
3 x 5 PBS-Tween Washing 
0.5 Hematoxylin Nucleus staining 
1.5 Tap water Blueing  
 
In order to confirm the proper binding of the primary antibody and the exclusion 
of false-positive signals, for every immunohistochemical analysis a control was 
performed. For this, IgG is used instead of a primary antibody by otherwise 
unaltered protocol to evaluate nonspecific staining. 
 
3.4.3 MTT assay 
 
The MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay is a 
colorimetric assay that allows for the detection of the metabolic activity of cells. 
The assay can be used to assess general viability of cells or provide a quantitative 
statement on the number of viable cells when performed under standardized 
conditions. The assay is based on the reduction of the orange MTT dye into 
purple formazan salt. The amount of produced formazan can be correlated with 
the number of viable cells [145]. 
The assay was used qualitatively to confirm the presence of viable cells in the 
vascular structures of the BioVaSc-TERM® as well as in collagen I hydrogels or 
on β-TCP granules or cylinders. The medium of the respective samples was 
aspirated and samples were washed with PBS+. Then they were transferred into 
a 50 ml conical tube and incubated with 9 ml MTT solution at a concentration of 
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1 mg/ml for 1 h at 37 °C in the incubator. Samples were washed with PBS+ and 
photographed with a digital camera or under the microscope. 
In contrast to soluble assays, the MTT allows the exact localization of viable cells 
due to the formation of the initially insoluble formazan inside the cells. 
 
3.4.4 Fluorescent staining 
 
DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) and DiO 
(3,3'-dioctadecyloxacarbocyanine, perchlorate ) are fluorescent dyes that are 
capable of inserting hydrocarbon chains into lipid bilayers of cells. This does not 
affect cell viability or basic physiological properties [146, 147]. The dye diffuse 
laterally in the cell membrane and thus stain the whole cell.  
In order to label cells 50 mg DiI were resolved in 54 ml of 100 % EtOH, while 
50 mg of DiO were resolved in 56.7 ml of 100 % EtOH. Cells were detached and 
resuspended in cell-specific, serum-free medium. Per 1 ml of cell suspension, 
5 µl of dye were added and an incubation at 37 °C for 20 minutes was performed. 
Cells were then centrifuged at 270 g for 5 minutes, the supernatant was aspirated 
and cells were washed with 10 ml medium. Cells were centrifuged and the 
washing step was repeated. Eventually, cells were seeded on ß-TCP granules at 
a density of 5.0 x 105 cells/ml.  
 
3.4.5 Acetylated low-density lipoprotein assay 
 
Low-density lipoproteins (LDL) serve as vehicle for lipophilic substances that are 
insoluble in blood plasma as for example cholesterol, fatty acids or certain 
vitamins. LDL can be transferred into cells by LDL receptors, which is not the 
case with Acetylated-LDL (Ac-LDL). In its acetylated form LDL is not recognized 
by the receptors anymore and only macrophages and endothelial cells can take 
it up via the so-called scavenger pathway that works independent of this 
recognition [148]. The uptake of Ac-LDL can thus be a hint on cell identity. EPCs 
isolated as described in 3.1.2.2 were examined regarding the uptake of Ac-LDL. 
EPCs were seeded into the wells of 4-well chamberslides at a cell density of 
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3.0 x 104 cells/cm2 in EGM-2 medium. After 3 days of culture the medium was 
aspirated and cells were incubated with EGM-2 medium without serum for 24 h. 
Subsequently, the medium was aspirated and 10 µl of Ac-LDL were added to 
each well. 4 h of incubation followed before each well was washed three times 
with PBS+. Fixation took place by 10 minutes of incubation in 4 % PFA.  
Following this, the samples were immediately analyzed under a fluorescence 
microscope. The used Ac-LDL is conjugated with the fluorescent dye Alexa 
Fluor® (Ex/Em 495/519 nm). During the experiments, all labeled Ac-LDL solutions 
were kept away from direct light in order to prevent bleaching of the fluorescent 
dye
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 Results 
 
4.1 Mobile Incubator 
 
A complex implant, produced at a manufacturing sitemight be far away from the 
clinical site where it is implanted. In this study, manufacturing and clinical site 
were 600 km apart. The transportation of the implants necessitated the 
development of mobile equipment that allowed providing a suitable environment 
for the live implants. The option of perfusing the vessel system was necessary as 
well as a constant temperature of 37 °C. 
 
Figure 1: CAD model of the mobile incubator. 
 
The design of the mobile incubator was executed using the 3D CAD Program 
SolidWorks by Dassault Systèmes (Figure 1). The housing was implemented with 
Adam Hall frame profiles with aluminium spacing. The incubation room was 
equipped with a 4-channel peristaltic pump and heating foils. The peristaltic pump 
featured 4 fittings for pumping tubes which allowed the perfusion of 4 implants in 
bioreactors at the same time. The bioreactor setup is depicted in Figure 2. 
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Figure 2: Schematic illustration of the bioreactor setup. 
The setup allows the perfusion of the bone graft in the mobile incubator: The peristaltic 
pump perfuses the vascular structures of the implant in the bioreactor while ensuring 
pressure conditions do not exceed 120 mmHg. 
 
Siemens SIMATIC ET 200S control unit regulated the pump and heating. For 
both units a desired value was predefined (temperature of 37 °C, pressure of 
120 mmHg). The control unit detected the actual values via temperature sensor 
and MEMSCAP SP844 physiological pressure sensor and compared the actual 
values to the desired values. Accordingly, it in- or decreased temperature as well 
as in- or decreased the rotational speed of the pump in order to maintain pressure 
conditions of 120 mmHg. 
The mobile incubator had to be operational using a standard power plug for 
stationary operation and via 12 V connector for transportational operation in a 
car. Due to the limited energy supply in a car, the components were assembled 
with their energy consumption in mind (Table 23). 
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Table 23: Calculation of electrical load. 
Rotational pump 24 V 1,25 A 30 W  
Heating foil 30 W 24 V 1,25 A 30 W  
Heating foil 20 W 24 V 0,833 A 20 W  
User interface 24 V 0,342 A 8 W  
Measurement amplifier 24 V 0,1 A 2,4 W  
Total   4,275 A 90,4 W  
 
Starting from 27 °C, the combined heat output of both heating foils heated the 
incubation room to 37 °C within 30 minutes (Figure 3). After 34 minutes, the 
temperature dropped due to turning off the device. 
 
Figure 3: Heating of the incubation room of mobile incubator. 
 
4.2 Endothelial progenitor cells 
Endothelial progenitor cells are a heterogeneous cell population. An 
extraordinary advantage of EPCs is, as soon as isolated, their expansion 
potential is very high and their easy accessibility. They can be isolated from easily 
harvested peripheral blood. This means a simple blood donation is sufficient to 
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gain access to this cell type. In contrast, the isolation of microvascular endothelial 
cells usually requires the removal of a piece of healthy skin from the patient. 
EPC were isolated from a volume of freshly taken blood from sheep and the 
mononuclear fraction was separated via density gradient centrifugation. 
 
Ovine EPC, day 1 Ovine EPC, day 5 FITC-acLDL, day 5 
Donor 1 
A B C 
   
Donor 2 
D E F 
   
Figure 4: EPC isolated from peripheral blood. 
Light microscopic images of isolated ovine EPC at passage 1, 1 (A,D) or 5 days after 
seeding (B,E). Fluorescent images of FITC-acLDL labelled EPC 5 days after sedding (C, 
D). 
 
4.3 Differentiation of human and ovine mesenchymal stem cells 
The differentiation of ovine MSCs into the 3 lineages adipogenic (Figure 5), 
chondrogenic (Figure 6) and osteogenic (Figure 7) was successful. The Oil red 
O staining revealed accumulation of fat droplets in the human and ovine cell 
bodies after incubation in adipogenic differentiation medium. 
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 Adipogenic differentiation Control 
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Figure 5: Histological analysis of human and ovine MSC differentiation. 
Oil red O staining indicating the formation of red stained oil droplets in human and ovine 
MSCs after treatment with adipogenic differentiation medium. No visible oil droplets in 
the controls treated with MSCGM. Scale bar: 100 µm. 
 
The chondrogenic differentiation potential of human and ovine MSCs was 
confirmed alcian blue and immunohistochemical staining for collagen II. The 
deposition of chondrogenic extracellular matrix and the expression of collagen II 
indicated a successful differentiation of MSC from both sources into 
chondrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
65 
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Figure 6: Histological and immunohistochemical analysis of human and ovine MSC 
differentiation. 
The immunohistochemical staining of collagen II shows the expression of the 
corresponding antigen in human and ovine MSC after treatment with chondrogenic 
differentiation medium. The alcian blue staining resulted in strong staining in the 
differentiated cells of human and ovine origin. No signal was detected in collagen II 
staining while the alcian blue staining was weak after the culture of the cells with 
MSCGM. Scale bar: 100 µm. 
 
Osteogenic culture of human and ovine MSC drove the cells into the osteogenic 
linage confirmed by alizarin red staining that stained the formed calcium 
phosphates red. 
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Figure 7: Histological analysis of human and ovine MSC differentiation. 
Alizarin red stained human and ovine MSC after culture in osteogenic differentiation 
medium for 28 days. The staining highlights the formation of calcium phosphate deposits. 
Controls show no sign of calcium phosphate production. Scale bar: 100 µm. 
 
4.4 BioVaSc-TERM® decellularization  
The BioVaSc-TERM® was the basis for the vascularization of the bone implant. 
After decellularization of the jejunum of a porcine small intestine, the BioVaSc-
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TERM® is a nonimmunogenic collagen I/III scaffold with preserved vascular 
structures.  
In order to confirm that the scaffold is cell free and that there is no residual DNA 
that could cause immunogenic reactions or otherwise compromise the 
functionality of the scaffold, H&E and Feulgen stainings were performed. 
 
Feulgen Feulgen Control H&E H&E Control 
A 
    
B 
    
C 
    
Figure 8: Staining of ECM of deceullularized porcine small intestine segments 
(BioVaSc-TERM®). 
DNA contend of decellularized scaffolds as compared to native intestinal samples. Scale 
bar: 100 µm. 
 
The Feulgen staining of 3 samples (Figure 8) indicates the successful removal of 
DNA during the decullularization process. In comparison to the positive control 
samples, there is no accumulation of blue dye detectable and thus no DNA in the 
samples. H&E staining confirmed the results, no nuclei were detected (blue color) 
and additionally the desired preservation of collagenous structures in pink color 
was indicated. 
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At the end of the decellularization process, the vessel integrity was checked by 
perfusing the scaffold via the arterial inlet with 2 ml of 0.5 % phenol red. This 
procedure gave information on the physical integrity of the vascular structures of 
the scaffold, which is one of the prerequisites for the functional application of the 
BioVaSc-TERM®. A successful decellularization process resulted in an even 
perfusion of all vascular pedicles and their subsequent branching (Figure 9: A, 
B). At the same time, the dye should not leak from any holes or damaged vessels. 
Accordingly, the produced scaffolds were graded from 1 to 6, with 1 being best 
and 6 the worst. Scaffolds that were only partly perfused due to blockades, that 
were punctured and leaked, were discarded (Figure 9, C; grade 6). Only scaffolds 
with perfectly preserved vascular structures were used for the production of 
implants (Figure 9, A, grade 1). 
A B C 
   
Figure 9: Quality assessment of decellularized porcine jejunum (BioVaSc-TERM®). 
Vascular structures of the BioVaSc-TERM® perfused with 0.1 % phenol red to check 
vessel integrity.
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4.5 GMP conform documentation system 
A standard operating procedure (SOP) for the manufacturing of the BioVaSc-
TERM® ensured the consistent quality of produced matrices with a structure as 
follows: 
Table 24: Structure of SOP for the production of the BioVaSc-TERM®. 
1. Abbreviations 
2. Function of the instruction 
3. Responsibility 
4. Applicability 
5. Supply and equipment 
5.1. Reagents 
5.2. Consumables 
5.3. Devices 
6. Description of the individual process steps 
7. Documentation 
8. Applicable documents 
9. Revision tracking  
 
The SOP defines its purpose and scope before indicating the responsible person 
for the document and the area of application. All necessary materials, chemicals 
and devices used are listed. The manufacturing section represents every process 
step in detail as described in the methods section of this thesis. The SOP 
concludes with a reference to the corresponding manufacturing protocol and an 
indication of applicable documents and revision tracking. 
Manufacturing protocols (MP) accompanying the SOP are the specific 
documentation of executed working steps. The document is preformulated and 
only requires ticking of every step performed in a printed document. Critical steps 
(e.g. preparation of the decellularization solution) demand the principle of dual 
control that has to be confirmed by signature in the document. 
The documents are supervised, checked and by the head of production, 
regarding manufacturing, while the head of quality control is responsible for 
documentation regarding quality control as required from the GMP principles.  
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As part of quality control, reagents, consumables and devices are defined in 
specification sheets and supplemented with a “Certificate of Analysis” for every 
batch ordered. 
Table 25 summarizes the results of the quality control of the produced BioVaSc-
TERM®s regarding vessel integrity by phenolred evaluation (grading 1 to 6), total 
bile assay evaluation (threshold <50 µM/l), endotoxin content (threshold 
<1 EU/ml), Feulgen evaluation (+, o, -) and H&E evaluation (+, o, -). 
 
Table 25: Quality control overview of decellularized BioVaSc-TERM®s. 
BioVaSc-
TERM® 
No. 
Phenolred 
evaluation 
1-6 
Total Bile 
Acid 
Assay 
evaluation 
<50µM/l 
Endotoxin 
<EU/ml 
Feulgen  
evaluation 
+,o,- 
H&E 
evaluation 
+,o,- 
B24.2  / √ / - o 
B25.2  / √ / + + 
B25.3  / √ / o o 
B25.5  / √ / o - 
B26.1  / √ / + o 
B26.2  / √ / o o 
B27.1 2 √ / o o 
B27.3 2 √ / - - 
B28.1 2 √ / o o 
B28.2 1 √ / + + 
B28.3 2 √ / + o 
B28.5 2 √ / + + 
GMP 
B25 
1 X X - - 
GMP 
B35 
1 √  / - o 
GMP 
B49 
1 √ √ + o 
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BioVaSc-
TERM® 
No. 
Phenolred 
evaluation 
1-6 
Total Bile 
Acid 
Assay 
evaluation 
<50µM/l 
Endotoxin 
<EU/ml 
Feulgen  
evaluation 
+,o,- 
H&E 
evaluation 
+,o,- 
GMP 
B51 
1 √ √ + o 
GMP 
B54 
1 √  /   - 
B29.3 1 √  / o o 
B29.4 1 √  / - - 
B29.5 1 √  / - + 
B30.1 1 √  / - o 
B30.2 1 √  / o o 
B31.2 1 √  / o o 
B32.1 1 √  / + + 
B32.4 1 √  / o o 
B33.2 1 √  / o o 
B33.3 1 √  / o o 
B33.4 1 X  / - - 
B34.2 1 √  / o o 
B34.3 1 √  / + o 
B35.1 1 √  / o o 
B35.2 1 √  / o o 
B35.3 2 √  / o o 
B36.1 5 √  / - o 
B36.2 5 √  / o o 
B36.3 3 √  / + + 
GMP 
B53 
3 √ √ + + 
GMP 
B55 
1 √ √ + o 
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BioVaSc-
TERM® 
No. 
Phenolred 
evaluation 
1-6 
Total Bile 
Acid 
Assay 
evaluation 
<50µM/l 
Endotoxin 
<EU/ml 
Feulgen  
evaluation 
+,o,- 
H&E 
evaluation 
+,o,- 
GMP 
B56 
1 √ √ + + 
GMP 
B57 
1 √ √ + + 
GMP 
B58 
1 √ √ - + 
GMP 
B59 
1 √ √ + + 
B38.1 6 √  / + + 
B38.4 3 √  / o o 
B39.1 2 √  / o - 
B39.2 5 √  / - - 
B39.3 4 √  / - - 
B39.4 3 √  / o - 
B39.5 4 √  / - o 
B40.1 1 √  / o o 
B40.2 2 √  / - - 
B40.3 3 √  / - - 
B40.4 4 √  / o - 
B41.1 2 √  / o + 
B41.2 1 √  / - - 
B41.5 1 √  / o o 
B42.1 2 √  / + o 
B43.1 1 √  / - - 
B43.3 6 √  / + o 
B44.2 2 √  / + o 
B44.3 2-3 √  / + o 
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BioVaSc-
TERM® 
No. 
Phenolred 
evaluation 
1-6 
Total Bile 
Acid 
Assay 
evaluation 
<50µM/l 
Endotoxin 
<EU/ml 
Feulgen  
evaluation 
+,o,- 
H&E 
evaluation 
+,o,- 
B45.1 1 √  / + + 
B45.2 2 √  / o o 
B45.3 2 √  / + + 
B45.4 4 √  / + o 
B46.1 2 √  / + + 
B47.1 4 √  / + + 
B47.3 3 √  / + + 
B47.4 3 X  / + + 
B48.3 3 √  / o o 
B48.4 2-3 √  / + + 
B49.1 1 √  / + + 
B49.2 1 √  / + + 
B49.3 3 √  / + + 
B50.1 3 √  / + + 
B50.2 1 √  / + + 
B50.3 2 √  / + + 
B50.4 3 √  / - o 
B51.1 1 √  / o o 
B51.2 1 √  / + + 
B51.3 2 √  / o + 
B51.4 6 √  / + + 
B51.5 1 √  / o o 
B53.1 2 √  / + o 
B55.1 1 √  / + + 
B55.3 1 √  / o + 
B56.1 1 √  / + + 
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BioVaSc-
TERM® 
No. 
Phenolred 
evaluation 
1-6 
Total Bile 
Acid 
Assay 
evaluation 
<50µM/l 
Endotoxin 
<EU/ml 
Feulgen  
evaluation 
+,o,- 
H&E 
evaluation 
+,o,- 
B56.2 3 √  / - o 
B56.3 2 √  / + o 
B57.1 5 √  / + + 
B57.2 1 √  / o - 
B58.1 1 √  / o o 
B58.2 5* √  / o + 
B58.3 1 √  / o + 
B59.1 6 √  / o + 
B59.2 1 √  / + + 
B59.3 2 √  / o + 
B59.4 6 √  / o + 
B60.1 3 √  / o o 
B60.2 1 √  / + o 
B61.1 1 √  / + + 
B61.2 5 √  / + + 
B61.3 1 √  / + + 
B62.1 1 √  / + + 
B62.2 1 √  / o o 
B62.3 1 √  / + + 
B62.4 1 √  / + o 
B62.5 1 √  / + o 
 
When initially total bile or endotoxin values were not met, additional washing 
steps could be introduced for a sufficient reduction of the respective value. 
Personnel experienced with histological assessment conducted the evaluation of 
H&E and Feulgen staining with positive and negative samples as reference in 
order to achieve objective results.
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4.6 Seeding of TCP granules  
The bone mineral aspect of the implants consisted of ß-TCP granules that were 
augmented by the seeding with MSCs. The successful seeding was confirmed 
by florescent DAPI staining. After seeding and 3 days of incubation under 
standard cell culture conditions, granules were plastic embedded and sectioned.  
A B C 
   
   
Figure 10: ß-TCP granules seeded with MSC.  
DAPI staining of MSCs seeded on ß-TCP granules in a peripheral region (A) and central 
areas (B, C). Scale bar 50 µm. 
 
4.7 BioVaSc-TERM® reseeding 
The functionality of the BioVaSc-TERM® as a scaffold providing vascular support 
could only be ensured when it was successfully reseeded with endothelial cells. 
The scaffold was seeded with ovine endothelial progenitor cells. The MTT assay 
with results in the conversion of the orange MTT dye into purple formazan. 
A B 
  
Figure 11: BioVaSc-TERM® after resseding with EPCs. 
MTT staining of EPCs seeded in the vascular structures of the BioVaSc-TERM®after 1 
(A) and 2 (B) weeks. Purple color indicates live cells. Scale bar 1 mm. 
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Figure 11 illustrates the successful population of vascular structures in a 
BioVaSc-TERM® with EPCs. The vessels and capillaries were evenly stained by 
the converted MTT indicating the presence of metabolically active cells. The MTT 
assay makes no statement on the identity of the cells that convert the salt. An 
immunochemical staining for CD31, an endothelial marker, confirmed the 
presence of antigens typically found in endothelial cells (Figure 12). The staining 
reveals the brown colored location of the CD31 antigen in vascular structures in 
the luminal areas (Figure 12: A, B) of the BioVaSc-TERM® as well as in the 
vascular pedicles Figure 12: C, D magnification of C).
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Figure 12: Immunohistological staining of section of reseeded BioVaSc-TERM®. 
CD31 staining of sections of the lumen (A, B) and den pedicle (C, D) of the BioVaSc-
TERM®. Scale bar: 100 µm. 
 
 
4.8 Animal experiment: Tibia defect in sheep 
In order to test the generated implants they were implanted into a 3 cm tibial 
defect in sheep. To this end, a part of the tibia was excised and the periosteum 
at the proximal and distal bony ends was further removed for one additional 
centimeter in order to test the regeneration potential of the implant and not the 
native periosteum (Figure 13, A). However, the BioVaSc-TERM® was brought 
into the defect together with the ß-TCP filling in a way that it should mimic the 
function of the periosteum. In this case, the arterial and venous pedicles were not 
anastomosed to the sheeps’ circulatory system but the scaffold was only pulled 
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over the bony ends with the ß-TCP filling the empty area of the defect. Sutures 
brought the scaffold and the native periosteum into close contact with each other 
(Figure 13, C).  
 
A B 
 
 
  
C D 
  
  
Figure 13: Tibial defect creation and bone graft implantation. 
The tibia was exposed and a 3 cm defect created (A). The bone implant (B) was put over 
the proximal and distal ends of the bony defect and the BioVaSc-TERM® was sutured to 
the native periosteum (C). The defect was fixed with reconstruction plates (D) and the 
wound was closed. 
 
One reconstruction plate with four screws proximally and three screws distally 
stabilized the defect. The stabilization was stable in all sheep, there were no 
adverse reactions, no loosening of screws or breakage of plates. 
After 6 months, the sheep were sacrificed and samples were taken. 
Samples were fixed in 4 % PFA and the following histological analyses were 
performed at the Julius-Wolf-Institue, Charité, Berlin. In an overview, the Van 
Kossa staining of the samples of all six sheep show mineralized tissue in black 
and connective tissue in red. A complete bridging is not visible in the samples.  
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Figure 14: Histological staining of tibial samples of different donors. 
Van Kossa staining of longitudinal sections of ovine tibia in the area of the defect site. 
Scale bar: 5 mm. 
 
However, regeneration of the bony ends towards each other is apparent in all 
samples, especially in samples of sheep A and F. Progress of regeneration is 
advanced and only a connective tissue layer of about 1 mm separates the 
proximal and distal part of the tibia. The staining reveals amounts of connective 
tissue embedding the remaining ß-TCP that was brought into the defect during 
implantation, while the regenerated bone is in places where there is no ß-TCP 
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left, an indication for osteoclastic activity that resorbed parts of the synthetic 
material. 
The immunohistochemical staining of α–smooth muscle actin in red color showed 
smooth muscle, which was an indication for vessels in the sample. 
 
 
Figure 15: Immunohistochemical staining of tibial implant sample D. 
α-smooth muscle staining of longitudinal section of ovine tibia in the area of the defect 
site. Scale bar: 5 mm. 
 
Figure 12 shows an overview of sample D (Figure 14) and details indicated. The 
presence of red circular areas was detectable in the bright structures, 
representing regenerated bone, as well as in the black depicted synthetic 
material. The results are consistent over the samples of the different donors. The 
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blood vessels were distributed over the entirety of the defect site and consisted 
of various calibers. 
µCT analysis of all samples are shown in Figure 16. Accordingly, to the histological 
results, there was no continuous union apparent and granules of the ß-TCP were 
identified.  
 
Figure 16: Bone regeneration after 6 months. 
µCT analysis of the defect site in the tibia of 6 sheep. Scale bar: 1 mm. 
 
The amount of dead space varied between samples. While sample A, D and F 
were filled out with dense material, bone or ß-TCP, samples B, D and E showed 
greater amounts of blank space in the µCT. This was an indication for soft 
material, e.g. soft tissue.
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4.9 Animal experiment: Defect in the mandibular angle in sheep 
In contrast to the experiments with the tibia defect, the bone graft filling a defect 
in the mandibular angle, were implanted with an anastomosis of the arterial and 
venous pedicles of the BioVaSc-TERM®. The implants were anastomosed to the 
facial artery and the accompanying vein in order to provide a connection to the 
blood circulatory system (Figure 17 C) and thus, nutritional supply to the cells 
inside. The site of implantation was the mandibular angle after the creation of a 
continuity defect. Stabilization was secured by two reconstruction plates fixed 
with osteosynthesis screws. The BioVaSc-TERM® itself was brought into the 
defect, the anastomosis was performed and the open ends of the lumen of the 
implant were pulled over the leading edges of the bony ends of the defect. 
Subsequently, the implant was covered by a titanium mesh that protected the 
implantation site and prevented a possible prolapse of the masticatory muscles. 
Anastomosis was performed and reperfusion of the vascular structures of the 
implant was observed for at least 15 minutes. During that time, the vasculature 
pulsated and no major leakage was apparent (Figure 14, D)
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Figure 17: Mandible defect creation and bone graft implantation. 
The defect was created in the mandibular angle and stabilized (A). Bone graft during 
implantation (B). Anastomosis of the graft with the host’s vasculature (C). Arterial inlet 
was anastomosed to the facial artery (circle). Dotted line indicates native arterial vessel, 
solid line the arterial inlet of the implant. (D) Following the induction of the blood flow, the 
blood enters the vasculature of the BioVaSc-TERM® (D).
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Figure 18: X-ray follow up after 6 months. 
Defect site of the control animal (A) and the defect site of the implanted bone graft (B).  
 
6 months after implantation, x-ray analysis showed the bridging of the defect in   
the sheep treated with the bone graft, while the defect in the control group was 
still present with no signs of bone regeneration. Figure 15 shows clear bone 
growth into the defect site with a completing union of the defect ends. However, 
signal intensity of the regenerated bone is lower than of the healthy native bone, 
indicating also a lower bone density. After sacrification, samples were plastic 
embedded and analyzed by toluidine-o staining. The treatment group of the 
implanted and anastomosed BioVaSc-TERM® showed signs of regeneration and 
remodeling. Bone formation occured adjacent to the cutting planes. The ingrowth 
of dense bone into the defect ended after ¼ of the original defect size and passed 
over to small bony island and ß-TCP bone replacement material. Although this 
was no large continuous bone area, the defect site was completely filled with 
small bone islands of 50 – 200 µm in dimension (Figure 19, A, C). They were 
evenly distributed over the whole defect site and were depicted as lightly brown 
stained areas. The dark black areas indicate remaining ß-TCP that was not yet 
resorbed
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Figure 19: Transverse section of the mandibular angle defect treated with BoneVaSc® 
bone implant analyzed by toluidine-O staining, 6 months after implantation. 
Overview of the defect bounded above and below by the collagenous structure of the 
BioVaSc-TERM® (A). Blue-stained laterally-oriented collagen fibers (white dotted lines) 
showed the course of the BioVaSc-TERM® preventing the ingrowth of connective tissue 
from outside the defect (B). Bright circular structures represent blood vessels of variable 
diameter within the formed tissue. Blood vessels and remaining ß-TCP material (black 
structures) embedded in newly formed bone tissue centrally in the defect (C). Scale bar: 
500 µm. 
 
The BioVaSc-TERM® was identifiable as a zone of parallel-oriented fibers at the 
outer rim of the ossifying area (Figure 19, B). This region contained many circular 
structures that were identified as blood vessels. The quantity of blood vessels 
Results 
85 
 
was highest in the BioVaSc-TERM® structure and evenly distributed over the 
whole defect site at a slightly lower concentration. 
The detailed examination of a single bone island revealed the morphology of an 
osteon (Figure 20). The mineralized core is interspersed with osteocytes and 
spreading canaliculi. The outer rim of the osteon was densely seamed with bone 
lining cells (Figure 20, B). The osteon was centrally traversed by a prominent 
blood vessel (150 µm diameter) with erythrocytes visible inside the vessel (Figure 
20, A). 
A B 
 
 
Figure 20: Transverse toluidine-O stained section of the mandibular defect treated with 
the bone implant after six months. 
Osteon embedded in collagenous tissue with blood vessels passing through (A). Detail 
of an osteon (B) showing osteocytes with canaliculi (black arrows) and lining cells 
surrounding the osteon (white arrows). Scale bar: 100 µm
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In contrast, the control sample showed light bone regeneration at the resection 
sides, the defect site was exclusively filled with soft tissue that is hardly 
cellularized. The presence of blood vessels was reduced in comparison to the 
treatment group. 
A 
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Figure 21: Transverse toluidine-o stained section of the mandibular defect control after 
six months.  
Overview of the defect (A). Detail of the peripheral area (B) showed connective tissue 
with a decreasing number of blood vessels towards the central area (C). 
Scale bar: 500 µm. 
 
Discussion 
87 
 
 Discussion 
The reconstruction of large and complex bone defects remains a challenge in 
reconstructive surgery despite bone’s immense healing capacity. Ablative tumor 
resection, osteomyelitic bone removal, severe trauma or bone necrosis can result 
in defects exceeding the natural regenerative potential. The defect size as well 
as the quality of the surrounding tissue and the condition of the wound bed, the 
local vasculature and potential infections influence the healing perspective.  
The aim of the thesis was the development of a prevascularized bone implant.  
Hence, a naturally derived scaffold of porcine origin (BioVaSc-TERM®) built the 
basis for vascularization and combined with synthetic material β-TCP, commonly 
used in bone reconstruction, resulted in the BoneVaSc-TERM®. Seeding of the 
BioVaSc-TERM® with EPCs restored its vascular functionality, while MSCs 
enhanced the osteogenic potential of the bone substitute material during implant 
maturation in in vitro culture. 
Subsequently, the implantation into a large animal model allowed for investigation 
of the effect in a tibial and a mandibular defect in sheep, comparing the 
regenerative outcome in case of using or not using the implant’s innate 
vasculature. The result in the tibial regeneration without blood vessel 
anastomosis showed a mainly supportive function in osteoconduction while the 
anastomosed implant in the mandible defect achieved the formation of numerous 
bony islands evenly distributed all over the defect site with extended vasculature. 
An additional aim was the optimization of the manufacturing processes in order 
to bring such an implant as close to clinical supplication as possible. As a result 
the production of the BioVaSc-TERM® fulfills the necessary regulatory criteria by 
being GMP-conform, including the necessary documentations and quality 
controls. 
 
5.1 Mobile incubator  
The thesis included the design of a mobile incubator and bioreactor system for 
the long-distance transportation of the bone implant between the site of 
production and the site of clinical implantation. This scenario is of clinical 
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relevance since clinics might not have the capacity and necessary infrastructure 
for the local production of complex implants. Thus, a transportation over long 
distances becomes necessary. Since the implant at hand consists of several cell 
types, their requirements to their environment had to be fulfilled in order to secure 
the quality of the implant. Thermoregulation was implemented for optimal 
conditions as they are found in standard cell culture. The application of 
endothelial cells in the vascular structures of the implant necessitated the 
implementation of an option for perfusion of the vascular system. This was 
realized by the equipment of the mobile incubator with peristaltic pumps. The 
shear stress resulting from the perfusion of the vasculature is necessary for 
endothelial differentiation and endothelial cell maintenance. Shear stress for 
example regulates the expression of markers associated with cell adhesion and 
endothelial differentiation [149]. Additionally, this is important for vascular 
resilience by stabilizing cell-cell interactions and influencing endothelial cell 
proliferation, migration and survival [150]. A physiological pressure sensor 
integrated into the medium circulation via pressure dome performed the 
monitoring of the pressure inside the vasculature of the construct. The control 
integrated into the mobile incubator adjusted the pumping speed of the peristaltic 
pump in order to establish pressure conditions that are similar to the physiological 
situation, facilitating mechanical stimulation of the endothelial cells. A Peltier 
element that allowed heating of the incubation room to 37 °C as well as cooling 
down the system in case of direct sun exposure of the mobile incubator during 
summer achieved temperature control. The mobile incubator offered convenient 
digital monitoring of pressure regime and temperature progression of the implant, 
parameters relevant for assuring quality of the implant. Their recording is also 
required by GMP guidelines. Power supply via 220 V or 12 V power plug allowed 
for stationary as well as mobile operation in a car. Concluding, the mobile 
incubator system is a tool that covers all the necessary aspects for a secure 
transportation of an implant in a clinical context. The principle of the mobile 
incubator could easily be transferred to other complex implants or even organs 
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5.2 Animal models 
 
There is a range of animal models available for bone regeneration and bone 
substitute material development [151–154]. Optimally, a suitable model should 
be reproducible, versatile regarding investigated materials or strategies and allow 
for several types of analysis. Influence of age and sex on bone regeneration 
through calciotrophic factors have to be considered [156]. The model should allow 
the generation of sufficient data, morbidity should be low and the costs 
reasonable [157].  
The use of animals in experiments is discussed controversially and their value of 
predicting a human response is not self-evident. However, this transfer of 
observations is necessary for animal experiments to be valuable for medicinal 
progress. Principally, the correlation of in vitro and animal models with the human 
condition and the subsequent equalization of the in vitro and animal model 
response to certain conditions and the human response is an assumption. If this 
assumption is not critically challenged, the data gathered from in vitro or animal 
experiments may contribute to a vast amount of information that has little contact 
to the true medical demands [158].  
Horrobin formulates examples that illustrate the lack of congruence of in vitro and 
in vivo models: The anatomical conditions and cell populations present in vitro 
and in vivo are different. The composition and availability of nutrition and oxygen 
supply, as well as carbon dioxide and metabolite removal are different. Conditions 
of cell multiplication are different. The quantity and participation of hormones 
together with their kinetic changes differ. The quaternary structure of proteins is 
dependent on the phospholipid composition of cells, which differs in cells in 
culture and cells in vivo. The membrane lipid microenvironment plays an 
important role in protein binding and thus, the function of proteins of cells in vitro 
and in vivo might differ [158, 159]. The critical discussion of the comparability of 
in vitro and in vivo experiments does not exist to a greater extend. This often 
results in the claim for abolishing animal experiments in favor of in vitro 
experiments, while the in vitro data cannot accurately reflect the human condition. 
An animal model can, under certain circumstances, deliver valuable insight into 
human disease. The prerequisites for a gain of knowledge are a comprehensive 
Discussion 
90 
 
understanding of the animal model and the same degree of understanding of the 
human disease as well as the examination of both conditions regarding 
congruence [158]. 
In the following, different animal models are presented for the investigation of 
bone regeneration and the similarities and differences to human bone structure 
and regeneration as already published in Current Molecular Biology Reports 
[160]. 
Depending on the aspect of investigation, different animal models can be taken 
into consideration. The most common species are rodents (mice and rats) that 
make up more than three-fourths, while pigs, rabbits, dogs, small ruminants and 
non-human primates represent the remaining model organism [161].  
Rodents are easy in handling and they can be held in high numbers to generate 
statistically significant data. Mice are commonly used to conduct specific or 
conditional knockout studies. Athymic nude mice allow for the investigation of 
osteoconductive materials from allogenic or xenogeneic sources of which the 
immunogenicity is unclear [161].  
Differences in general bone healing potential of animals as well as differences in 
the micro- and macrostructure in comparison to human bone regeneration are 
important to consider. The ratio of cortical and cancellous bone determine the 
biomechanical properties of the specific bone investigated [162]. Open growth 
plates in the epiphyses of mice and other rodents retain their longitudinal growth, 
which is not available for adult humans [163].  
The Haversian system and closed growth plates in rabbits make them more 
suitable for a comparison to the human condition. Additionally, the bone density 
in both organisms is more similar, while shape and size of rabbit bones differ from 
the human anatomy, thus limiting the gain in knowledge regarding the 
investigation of mechanical properties [164]. Rabbit studies are commonly 
employed in cranial and mandible defects as well as age-related critical size 
defects using autologous cell-seeded or cell-free biomaterials, growth factors or 
the application of techniques as negative pressure [165, 166]. 
Canine models are used for periodontal and musculoskeletal research, the 
investigation of the regenerative potential of adipose-derived or bone marrow 
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stem cells and biomaterials. Dose-response studies of various growth factors 
were conducted [167, 168]. Structure, composition and remodeling rate of dogs 
and humans are similar which allows for the evaluation of implants that are 
suitable for human application regarding size. However, canine models are often 
critically viewed due to low social acceptance [169]. 
The regeneration process of pigs is similarly comparable to the one of humans 
as the one of dogs. Bone density of the trabecular network and increased bone 
strength in pigs differ from the human condition, while bone morphology, structure 
and composition closely resemble their counterparts. Common studies 
conducted with this model investigate fracture healing, femoral head necrosis or 
regulatory toxicity studies as well as testing of critical size bone substitutes, as 
the healing rate of pigs is similar to that of humans [170]. High growth rate, body 
weight and challenging handleability pose potential difficulties that were 
approached by the breeding of mini and micro pigs [171].  
From the start, sheep and goats are more convenient in handling, animal cost 
and social acceptance [172].  Their comparable anatomy in long bones and their 
suitable dimensions make them a preferential choice for testing implants intended 
for human use [173, 174]. Humans and sheep share a similar bone 
macrostructure with a difference in the ratio of primary and secondary bone. This 
can be accounted for by using sheep of an age of 7 – 9 years, when secondary 
bone modeling begins. In spite of minor differences in the microstructure, the 
resemblance in bone metabolism, turnover and remodeling is significant [175]. 
Sheep have been used for segmental defect models [176], vertebral bone defect 
models including studies testing bone substitute materials [177], the effect of 
growth factors [178], and tissue engineering strategies [154]. While the use of 
small animals is convenient for many models, large animal studies are necessary 
to study the feasibility of methods or the sheer size to accommodate implants of 
a dimension that requires prevascularization and anastomosis when otherwise 
the survival of seeded cells would be affected. The data generated from large 
animals can be more comparable regarding biomechanical analysis and 
necessary surgical procedures can be evaluated for their suitability and redefined 
when appropriate. For this reason, the experiments of the thesis employed the 
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sheep model despite its increased complexity. The animal model was an ovine 
model for a segmental bone defect in the tibia [179] and a newly developed 
mandibular defect model by Rasse and Stigler (Clinical Department of 
Craniomaxillofacial and Oral Surgery, Medical University of Innsbruck). In both 
cases, the size of the implant was of clinically relevant dimensions. The tibia 
defect was easily accessible and offered a relatively simple possibility to suture 
the BioVaSc-TERM® to residual periosteum (Figure 13 C). Important in this 
scenario was the removal of the native periosteum over the defect itself so that 
the regeneration would be contributed to by the BioVaSc-TERM® alone. The 
mandibular defect model was chosen for relevance and challenge. Animals like 
sheep show a comparable operative situs, as in humans in respect of bone 
dimensions or vessel diameter. These aspects suggested a feasible transfer to 
the clinical situation in humans for the surgical techniques used in this study can 
be easily conveyed to the human anatomy due to the high degree of anatomical 
homology in the cranio-maxillofacial area. 
In the mandibular model, the particular challenge lied in sheep being ruminants, 
so the mechanical requirements in this constellation exceed the human situation 
significantly. In sheep, the daily rumination is estimated with 600 min/day with 62 
– 80 chews/min, resulting in 37,200 – 48,000 chews per day [180]. Two 
reconstruction plates fixed with osteosynthes screws were used to stabilize the 
defect. None of the sheep suffered from insufficient stabilization or breakage of 
the plates. Precedent biomechanical tests demonstrated the suitability of the 
method and ruled out the fixation with one plate only (experiments not shown, 
Medical University Innsbruck, Department of Cranio-Maxillofacial and Oral 
Surgery, Innsbruck, Austria). 
The mandible defect is a clinically relevant scenario for ablative tumor resection 
or osteonecrosis caused by radiation or drugs as bisphosphonates in the 
maxillofacial context. The jaw angle below the musculus masseter was excised 
and stabilized with two titan plates and an additional titan cage. The 
prevascularized implant’s arterial inlet and vein were anastomosed with the host’s 
blood circulation via the facial transverse artery. 
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5.3 Bone graft implantation into critical size defects in sheep tibia 
and mandibale 
 
Many strategies for bone tissue engineering that have been clinically approved 
are single component approaches while the incorporation of several if not all the 
current aspects of bone engineering might be necessary for successful bone 
regeneration in large defects [181]. In this approach, we employed and combined 
methods to address several clinically relevant aspects. 
The thesis placed focus on minimally invasive methods for the design of an 
implantable bone graft. MSCs could be easily harvested from bone marrow 
aspiration while their enormous expansion potential and their similarity to 
periosteum stem cells make them a predestined choice [182]. They have a history 
of application in preclinical models and indicated therapeutic activity in 
musculoskeletal settings [183], as they play a major role in bone fracture repair 
and can secrete VEGF in hypoxic conditions [184]. Autologous MSCs were 
harvest from sheep and seeded on ß-TCP granules that might already have an 
osteogenic induction effect on the cells during in vitro culture [185]. The material 
additionally served as a guide rail for bone regeneration after implantation in vivo. 
Population of this substrate with MSCs could trigger attraction of EPCs by growth 
factor expression [186]. EPCs were the second cell type chosen for the implant 
as they are known for enhancement of neovascularization of ischemic tissues via 
participation in actual vessel formation [187, 188] and paracrine effects [189]. 
EPCs fulfilled the requirement of being accessible minimally invasively due to the 
isolation by density gradient centrifugation from peripheral blood. MSCs and 
EPCs have distinct positive attributes that make them suitable for the construction 
of a prevascularized bone implant by themselves but additionally synergize in 
bone regeneration by enhancement of early vascularization and thus, 
accelerating the healing process [190]. To make use of the advantageous 
attributes of the EPCs, the BioVaSc-TERM® was employed. The general clinical 
applicability of the scaffold was demonstrated in a two-year follow up of a tissue 
engineered airway patch [191]. The degree of standardization of the scaffold is 
illustrated by a current review by local authorities for the application of the scaffold 
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as tracheal implant. The analysis of the scaffold after decellularization showed 
low levels of residual DNA in the Feulgen staining and few cell remnants in the 
H&E staining; essential preconditions for the implantation of the xenogenic 
scaffold since otherwise an immune response upon implantation into the target 
organism must be expected. The BioVaSc-TERM® was the basis for in vitro 
prevasularization of the bone implants and has hypothetical potential for 
mimicking periosteal functions in the context of bone regeneration. Osteogenesis 
and cortical blood flow are influenced by the periosteum. Accordingly, studies 
showed the promotion of bone formation and neovascularization after injury when 
healthy periosteum covered the damaged bone [192]. The absence of periosteum 
due to injury results in delayed healing or non-unions [193, 194] and there have 
been approaches at tissue engineering periosteum human dermal matrices [195]. 
With this in mind, the use of the BioVaSc-TERM® seems suitable at providing 
vascularization of an ischemic site in a critically sized bone defect. While the 
vascularization aspect was covered by the aforementioned measures, promoting 
bone formation was aimed at by filling the lumen of the BioVaSc-TERM® with ß-
TCP granules that were previously seeded with MSCs. Calcium phosphates are 
well-characterized materials that are commonly used in dental or craniofacial 
applications. In 1998, TCP has been approved for the repair of craniofacial 
defects by the Food and Drug Administration (FDA) [196]. It was used with good 
results for bone formation in sinus elevation [197, 198] and alveolar ridge 
preservation [199].  
The treatment of the tibia defect with the BoneVaSc-TERM® was performed 
without the direct anastomosis of the vessel system but in close vicinity to the 
neurovascular bundle running down the tibia. The results of the histological and 
radiological analyses show an inhomogeneous appearance of the regeneration 
site. Defect bridging occurred in one single of the specimen. Generally, bony 
growth occurred at the defect ends towards each other; areas of remaining ß-
TCP embedded in soft tissue as well as areas that predominantly contained 
connective tissue were detected. In all of the different compartments, blood 
vessels were identified by the α-SMA staining, suggesting the general 
accessibility of the defect site for angiogenesis. The aforementioned formation of 
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different tissue compartments appears to be unfavorable. While the bone 
regeneration seemed to take place only from the bony ends of the defect, the 
void space in the defect had been filled with connective tissue invading from the 
surrounding tissue. It might have been the case that the implants’ effect mainly 
lay in the provision of the ß-TCP as osteoconductive material but no profound 
integration of the implant into the regeneration process. The results of a 
preclinical study by Kaempfen et al. investigating the effect of decellularized bone 
reseeded with bone marrow derived MSCs in a rabbit segmental defect model 
were similar. Prevascularization was achieved by ectopic implantation into a 
muscle flap close to the defect site. In a second procedure the whole flap, 
including bone graft, was transferred into the defect while keeping the vessels 
connected to allow sustained blood flow [200]. The defect did not consolidate or 
remodel to a greater extend. Callus formation occurred around the graft, not 
including it. The defect site hosted an increased amount of blood vessels, 
however, bone formation itself was limited. These findings were in line with those 
of the BoneVaSc-TERM®’s non-anastomosed study.  
In contrast, the treatment of the defect in the mandible was performed including 
a direct anastomosis of the implant to the circulatory system of the experimental 
animals. The anastomosis of the BoneVaSc-TERM® scaffold to the facial vessels 
in the mandibular defect succeeded in all cases. Both the arterial inlet and the 
venous outlet of the BoneVaSc-TERM® were mechanically stable enough for the 
procedure. Observation of the implants for 15 minutes after reperfusion confirmed 
vessel patency. During that time, pulsating of the vasculature was detected in all 
implants with no leakage apparent. The successful anastomosis is an essential 
prerequisite making an implant more independent from the condition found inside 
the injury site. Analysis of sections from the defect site indicate a dense network 
of vessels of different caliber supplying the tissue, a relevant result since scaffolds 
often do not succeed in supporting viability on their inside [201]. 
In contrast to other studies [201, 202] the ß-TCP seemed not to be embedded in 
adjacent bone tissue, instead the granules appear to be resorbed by osteoclastic 
activity and at the same time replaced by newly formed osteons (Figure 20). 
Osteons are the basic functional unit of compact bone. The osteons found in the 
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defect exhibit an approximately cylindrical shape, which is their typical 
appearance [203]. Characteristic for an osteon is the centrally arranged 
Haversian canal containing a blood vessel, which supplies the osteon with 
essential nutrients. Figure 20 shows an osteon in detail with the blood vessel in 
the Haversian canal filled with tightly packed blood cells, identifiable by their 
discoid shape. The osteon was surrounded by bone lining cells with their generic 
flat shape. The presence of the bone lining cells might indicate a mature state of 
the osteon, as bone lining cells are one of three possible fates of osteoblasts 
upon the completion of forming bone matrix [204]. The other fates being the 
transformation into osteocytes and apoptosis [205]. As bone lining cells are 
considered quiescent cells “where neither bone resorption nor bone formation 
occurs” [5], the illustrated osteon might have reached its resting form, not 
contributing to any further bone formation. On the other hand, bone lining cells 
are associated with the initiation of resorption and bone formation, so that it is 
uncertain if the osteon would have grown in size with prolonged experiment 
duration or not [206]. The diameter of the Haversian canal diameter of about 160 
µm appears to be almost double the size as compared to human dimensions 
[207]. It has to be noted that, in humans, there is already a significant intraspecific 
variability in Haversian canal diameter depending on their origin, for example from 
ribs or femurs [208]. 
Rather than osteoconduction, bone formation by osteoinduction seemed to have 
taken place in ß-TCP as substrate. The osteoclasts and osteoblasts that 
participated in the formation of the osteons could have derived from the MSCs 
originally seeded on the ß-TCP granules or the circulatory system. The MSCs 
might have taken part in the attraction of vessels into the inside of the implant. 
No adverse effects were detected due to the autologous cell sources and the 
immunological inert biological and synthetic scaffolds. The results show an 
extensive vascular network in the anastomosed implants as compared to the 
control defect. In the control, the encountered tissue was mainly soft tissue of a 
low organizational level and no signs of bone formation in the central defect area. 
Only in the area of the resection rim of the continuity defect, there were hints on 
bone formation.  
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The role of the EPC in the experiments appeared to contribute mainly to 
vascularization while other authors found results suggesting a possible role of 
EPC in bone regeneration itself: In a sheep model, a 3.2 cm defect in the tibia 
was created and treated with EPC transplantation [81]. The defect was stabilized 
with stainless steel plates and the wound was closed. EPC transplantation took 
place 2 weeks later by opening the wound and creating a v-wedge-shaped 
longitudinal canal in the regeneration scar tissue. 2 x 107 EPCs were applied to 
the canal; the wound was closed subsequently. Until sacrification 12 weeks later, 
x-ray images were taken every two weeks while µCT and histological analyses 
were performed after scarification. X-ray images revealed the beginning of bone 
regeneration 2 – 4 weeks after surgery in the treatment group while the control 
group exhibited no or minimal bone regeneration. X-rays indicated complete 
bridging 10 – 12 weeks later in the treatment group, minimal bone regeneration 
in the control group. Histological methods provided confirmation of the preceded 
analyses by showing woven bone structures in the regenerated defect site in the 
treatment group. The contribution of EPCs to an improved bone regeneration by 
accelerated vascularization immediately suggests itself. However, authors stated 
that the scar tissue after 2 weeks already showed a high degree of vascularization 
before the application of EPCs so that a positive effect due to any further increase 
in vascularization did not seem to be necessary. Alternatively, the authors 
consider a possible differentiation into the osteogenic linage. There are hints on 
the possibility of EPCs expressing an osteogenic phenotype under bone 
differentiation conditions in vitro [74, 81], but the true fate of the EPC in this 
experimentation remained speculative. The main difference between this 
investigation and work at hand regarding EPCs was their number and 
administration. The isolation method of the EPCs matched in both approaches 
but Rozen et al. placed a greater number of EPCs directly into the defect site 
straight after expansion when they possibly remained rather undifferentiated. The 
EPCs in the mandibular defect on the other hand were subject to differentiating 
cues in the vessel system of the BioVaSc-TERM® by the 3D structure itself and 
the pressure regime induced by the bioreactor, driving the EPCs into the 
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endothelial lineage. Thus, they most likely fulfil their role as endothelial cell as 
opposed to the comparative study in which they might form bone. 
Furthermore, there have been reports on anastomosed implants following the in 
vivo bioreactor principle like free flap procedures or the utilization of AV loops 
with promising results [97, 107]. Such regeneration strategies are appropriate for 
the treatment of compromised transplant beds as they include a functional 
vascularization that makes them less dependent on the vasculature on-site. A 
dedicated implant vasculature provides the possibility of bringing the necessary 
requirements for successful healing as in endochondral ossification. The 
implant’s innate blood supply allows for uninterrupted formation of cartilage 
hypertrophic chondrocytes and their progression into bone [209]. Drawbacks of 
the aforementioned in vivo bioreactor principle and free flaps are the two 
necessary operations; the first that brings in the desired implant or material into 
the flap, and the second operation for taking the implant out of the ectopic site for 
the actual treatment of the defect in another site. Depending on the site of 
harvesting, the donor site morbidities can range from discomfort and pain to 
limited mobility [210]. Additionally, every surgery bears the risk of surgical site 
infection accounting for 400,000 extra days spent at hospital in the USA alone. 
This equals a cost of US$ 10 billion per year [211]. Surgical site infections are 
defined as infections occurring up to 30 days after surgery, affecting the incision 
or the underlying tissue at the operation site and the incidence rate can be up to 
20 % under unfavorable preconditions [212]. These steps were circumvented in 
the approach of the thesis by minimally invasive cell isolation from peripheral 
blood and bone marrow aspirate. The advantages of minimally invasive 
procedures over open procedures are a reduced incision area, earlier 
mobilization, and reductions in postoperative pain, better preservation of immune 
system function and decreased use of central venous catheters. The result is a 
significantly reduced risk for surgical site infections [213]. Following the same 
intention, Eweida et al. used a HA/β-TCP composite scaffold loaded with 
autogenous platelet-rich plasma BMP-2 in an attempt to induce bone formation 
in a defect in the mandibular angle of goats. After creating a defect without 
interrupting the mandible’s continuity  the bone graft was inserted and stabilized 
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with a titanium plate and screws [214]. The graft was anastomosed to facial 
vessels, creating an in situ AV loop already in the defect site. Investigations 
correlated bone growth with the central vascularization provided by the 
incorporated facial vessels. In contrast to the implants of this thesis, BMP-2, with 
its associated regulatory implications, was used and the defect created was 
marginal as opposed to the continuity defect in the sheep mandible. 
Summarizing the presented results, the bone formation itself has to be improved 
further; the vascular basis for defect regeneration is promising and might facilitate 
the establishment of bone continuity if allowed to regenerate for a longer period 
than six months as it was the case in the study presented. This approach is a 
feasible alternative to free nonvascularized bone grafts from iliac crest, ribs, chin, 
fibula or tibia that successfully treat defects with good transplant bed conditions. 
Vascularized bone grafts, as the one presented in this study, are more resistant 
to poor transplant beds as found in medication-related osteonecrosis or 
radiotherapy. Additionally, second site surgeries could be avoided which reduces 
the associated risk for patients and increases acceptance of the procedure. 
 
5.4 Consideration of the GMP principles 
In order to get closer to the aim of clinical application of research in the field of 
regenerative medicine, the GMP principles were taken into account during the 
production of the implants used in this work and implemented in the case of the 
production of the BioVaSc-TERM®. The health condition of the donor animals as 
raw material for the production of the BioVaSc-TERM® was an essential criterion. 
Accordingly, all animals came from a combined, closed breeding establishment 
and fattening farm and were approved for food production according to 
Regulation (EC) 853/2004. A veterinarian performed herd health monitoring at 
least once a month. Livestock was vaccinated preemptively against swine 
influenza, erysipelas, smedi, rhinitis atrophicans, mycoplasma hyopneumoniae, 
porcine circovirus type 2, porcine circovirus associated disease and porcine 
intestinale adenomatose. Every four months samples (nasal swaps, blood and 
fecal samples) were taken randomly for bacterial, parasitical and virological for 
analysis by the Bavarian state office for health and food safety Erlangen 
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(Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit Erlangen). 
For the past two years, the livestock had to be free from notifiable diseases, from 
zoonosis or infectious diseases of the gastrointestinal tract as well as endo- and 
ectoparasites. The decellularization process as described in chapter 3.2 took 
place in a class D clean room and ensured inactivation of enveloped viruses 
within 5 minutes to a level below the detection limit of the test at 4.5-log reduction. 
The subsequently performed gamma irradiation should result in a log-reduction 
of 4 – 5 for small non-enveloped viruses. The dose of gamma irradiation will be 
elevated to 31 kGy in order to fulfill guideline EMA/CHMP/BWP/814397/2011 and 
the efficacy will be validated in a viral clearance study in the future. For quality 
control, bile acid concentration (< 50 µmol/l), endotoxin (≤ 1.0 EU/ml), DNA 
content (weak Feulgen staining), cell residue (weak H&E staining), mycoplasma 
(negative) and microbiological testing (negative) were determined after gamma 
irradiation and only samples that fulfilled the criteria were released for further 
processing. Accredited contract laboratories using validated test systems 
performed the testing of mycoplasma, endotoxin and microbiology. 
The documentation of the process in manufacturing protocols allowed for 
complete trace- and replicability as required according to the GMP guidelines. 
The production of the BioVaSc-TERM® as basis for the prevascularized bone 
implants complied with regulatory requirements. The production, quality control 
and documentation met the requirements by local authorities and the Paul-
Ehrlich-Institut during an audit for the obtainment of a manufacturing 
authorization. An additional study demonstrating the virus safety regarding small 
non-enveloped viruses of the produces matrices will be carried out in future. 
The complete BoneVaSc-TERM® as a combination of the BioVaSc-TERM as 
medicinal product and cellular components (EPCs and MSC) make it a combined 
ATMP and subject matter of the Guidelines on Good Manufacturing Practice 
specific to Advanced Therapy Medicinal Products. The construction of the actual 
bone aspect considered the GMP standards in the choice of material and cell 
source, but it did not fulfill it in any aspect since in this part research was the 
focus, which does not allow for the rather inflexible GMP processing. From a 
regulatory point of view, this approach allowed the BioVaSc-TERM® to act as an 
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independent unit outfitted with manufacturing and documentation standards that 
can satisfy the strict demands necessary for a possible manufacturing 
authorization. As the BioVaSc-TERM® can be the basis for various 
prevascularized implants; a valuable foundation was created for the swift 
approval of such implants.
Outlook 
102 
 
 Outlook 
The subpopulation of EPC used in this work was not determined. They fulfilled 
their function regarding repopulating the vascular structures and making them 
functional. It might be able to enhance the osteogenic potential by using EPC 
derived endothelial cells that are specifically useful in bone regeneration. 
The maturation of the implant took place without the use of osteogenic culture 
medium, so initially the only impulse for the MSCs to commit themselves to the 
osteogenic lineage was the biomaterial. The main function and capability of the 
material lies in its osteoconductive properties and its task as guide rail; their 
osteoinductive impact, however, is low. The use of osteogenic differentiation 
medium during in vitro culture could bring the implant closer to its future area of 
application, the bone. This could potentially speed up the integration into and the 
regeneration of a defect. Another option to increase regeneration could be the 
incorporation of immobilized BMP into the biomaterial for example by covalent 
binding. This would allow for use of the protein at low dosages, which would 
circumvent the risks associated with the use of high dosages of BMP.  
Furthermore, an advanced in vitro maturation of the implant could provide a bone 
regeneration model that allows testing of other one regeneration treatment 
strategies, including growth factors, biomaterials or therapeutic cells. 
The results of the experiment of the anastomosed implant suggested a prolonged 
observation period of the experiments since there was substantial bone growth 
but no complete bridging with increased bone density. It would be of interest to 
investigate if the defect would heal completely after a longer experimental time 
or if the regeneration stopped at a certain point. Additionally, labeling techniques 
for cells populating the implant could deliver insight into the fate of the cells in 
vivo. Methods like cell labeling using iron oxides or perfluorcarbon are promising 
techniques as soon as their sensitivity can be increased to a level that allows for 
a non-invasive detection of a low number of cells in vivo. This could deliver more 
precise information on the function and fate of cells delivered.
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